BioInvent

10

Annual Report 2010

Contents

Preclinical research



Summary of a successful year

- Positive results from the phase II study of the antithrombotic TB-402 were reported in May 2010. The company's antibody demonstrated a clearly better effect and comparable safety in relation to the comparison drug (enoxaparin).
- New clinical study of TB-403 was performed in 2010. BioInvent and partner ThromboGenics recieved EUR 10 million milestone payment from Roche.
- A phase II study of BI-204 for the treatment of coronary artery disease was approved in November 2010 by the US Food and Drug Administration (FDA). The studies will be carried out in cooperation with partner Genentech, a wholly-owned company in the Roche Group.
- A product partnership with the US company Human Genome Sciences to develop and commercialise therapeutic antibodies was initiated in March 2010.
- Continuing recruitment and expansion of the ongoing phase I study of BI-505.



Comments by the CEO

In 2010 BioInvent continued to make progress with its product portfolio. The work that overshadowed everything else during the year for us and our partners involved advancing our four drug candidates in the value chain. We can now announce that our efforts were successful and our projects are taking new and significant steps forward in the clinical programme.

Last year was an eventful one in other ways as well. We improved our financial position through a successful issue of shares, joined up with a new partner to develop antibody drugs and decided to stop all contract manufacturing to instead focus our resources on producing antibodies for in-house drug development. Today BioInvent is a well-established and innovative biotech company with an international reputation that specialises in antibodies – one of the most important segments in the pharmaceuticals industry. All of our drug candidates represent new, unique methods for treating serious diseases where there is an unmet medical need.

A milestone that was therefore important to us was reached in the summer of 2010 when we were able to report positive phase II data for our antithrombotic, TB-402. The clinical study showed a clear improvement in the effect on patients undergoing knee surgery compared to the current standard treatment, enoxaparin. We achieved this result with a single dose of TB-402 following surgery, compared to daily treatment for at least ten days with enaxoparin. Our goal is to develop a product that can also be used for patients undergoing hip surgery. To this end, we are in the process of launching a phase IIb study involving such patients with the aim of showing that a single dose of TB-402 in connection with surgery can be at least as effective as a daily dose of the existing treatment for up to 35 days. Once we have been able to establish that TB-402 can compare favourably with other treatments in this indication, we intend to proceed in with a phase III programme that will include both knee and hip surgery. In parallel with the phase II study, we prioritise the work of identifying a commercial partner, which has the infrastructure to develop the product through late stage clinical development to full commercialisation.

Our partner Roche has decided to start two new clinical studies in the cancer project TB-403. One study will be carried out on patients with an aggressive form of brain tumour and the other on patients with severe liver cancer. Since these are indications with a great medical need, the development timelines to market may be relatively short if good effects can be shown.

Another phase II study will soon be launched after the US FDA in November 2010 approved BioInvent's plan for the continuing clinical programme for the atherosclerosis project BI-204. The study will be run in cooperation with our partner Genentech, and is expected to be reported in the first half of 2012.

We are expecting to report data from the clinical phase I study of our BI-505 drug candidate to treat multiple myeloma in the second half of this year. If the clinical results clearly indicate that we have the potential to develop a product that is differentiated from existing treatment methods, the goal is to take the next step of development of the product candidate in-house.

BioInvent considers the issue of partnership cooperation versus developing in-house development to be a crucial one. There may be good reasons to retain the rights to our drug candidates longer than we have done in the past. When projects advance in the value chain, their value increases and we are thus able to retain a bigger portion of the profit through more favourable terms in agreements with partners or through in-house development. At the same time, it is important for us to weigh the relative risks and costs involved in continuing with in-house development against the future commercial value in retaining the project.

We were working hard in 2010 to drive our drug candidates forward in the clinical process, and in parellel, we put considerable effort into identifying new preclinical research projects. We licensed new projects from academic groups, signed a comprehensive development agreement with the US company Human Genome Sciences and launched new, internal research programmes. Broadening our operations in this way is essential for the company's long-term growth.

The growing scope of our drug development activity was the reason for our decision during the year to stop all contract manufacturing of antibodies for external customers. We will need our production capacity as our projects advance in the value chain. Contract manufacturing has been a valuable source of revenue, but we are weighing the fall in revenues as we tailor production for our own needs against the cost reductions and income generated when our partners' use our antibody library.

"In 2010 BioInvent continued to make progress with the project portfolio."

Svein Mathisen, CEO

Additional evidence of the international interest in our Company emerged just before Christmas when one of our existing partners, an undisclosed Japanese pharmaceutical group, selected BioInvent for continued development of a drug candidate in the area of inflammation; a candidate that was generated from our antibody library. BioInvent considers this type of cooperation involving our antibody library to be extremely valuable. We receive income from our partners without taking on any significant risk ourselves. In a longer perspective, we receive milestone payments and royalties for the products that advance into clinical development and finally reach the market. We are therefore highly incentivised to ensure that our partners succeed in developing new product candidates.

The continued broadening and deepening of BioInvent's operations; a project portfolio that is developing well, new partnerships involving our antibody platform and a growing number of projects in preclinical development, will all contribute to making 2011 another eventful year for BioInvent.

In conclusion, I would like to express my deep gratitude to our staff for their hard work throughout another successful year.

Lund, March 2011
Svein Mathisen

Markets

Antibodies – an attractive drug category

The antibody-based drug segment is one of the fastest growing segments in the pharmaceutical industry. Since the beginning of 2000 sales have increased more than tenfold from USD 2 billion to around USD 40 billion in 2010. This strong growth is likely to continue over the next few years, and by 2014, the market is expected to be worth more than USD 60 billion[1]. There are several reasons why antibody-based drugs have become successful and represent significant value for the companies that have developed them. Antibodies are nature's own defence molecules. As such they are highly selective and, in their natural form, are very well tolerated by the body. A precise effect is noted and the antibody integrates naturally with the rest of the immune system which thereby can modulate the antibody's therapeutic effect. Also, antibody-based drugs to some extent have other application areas than traditional medicines; they are useful when targeted, for example, at extracellular molecules or cell-surface proteins – two significant groups of target proteins that may be difficult for traditional, small molecular drugs to impact. This is the task of naturally occurring antibodies of the organism: to recognise foreign substances and cells so that they can be rendered harmless.

The time needed to develop antibody-based drugs is shorter than for traditional pharmaceuticals and development costs are therefore lower. In addition, the risk of setbacks in clinical development appears to be lower for antibodies than for traditional drugs.

End markets for BioInvent´s Product Candidates

BioInvent currently has four product candidates in clinical development in the areas of thrombosis, atherosclerosis and cancer, diseases where there is a significant medical need. Below are brief descriptions of the markets for BioInvent's product candidates.

Thrombosis

TB-402 is being developed as a treatment to prevent thrombosis. In clinical trials reported during the year, the product candidate showed a significantly better effect than the comparison drug enoxaparin (Lovenox®, Sanofi-Aventis) in patients undergoing knee replacement surgery. The study also confirmed that TB-402 has a favourable pharmacokinetic profile and a comparable safety profile. BioInvent will conduct a phase IIb study for the prevention of deep vein thrombosis (DTV) following hip surgery. An equally promising but significantly larger market segment consists of patients who need thrombosis prophylaxis because they are immobilised, which is common in hospitalised patients, but also in many patients receiving care in other environments. These patients run a big risk of DVT unless they are treated with an antithrombotic drug. Currently this treatment is usually in the form of low molecular heparin, which needs to be injected daily. For these patient groups, who may typically need treatment for up to 30 days, long-acting TB-402 is expected to be an attractive alternative, since its antithrombotic effect is believed to last for the entire period after the patient is given the antibody on a single occasion. A third important group that may be able to be treated with TB-402 consists of patients with atrial fibrillation. These individuals run the risk of serious complications, such as stroke, unless they receive adequate treatment.

The mortality rate among patients with DVT is high if left untreated, and the cost for society as a result of the healthcare needs of these patients and their subsequent long-term follow-up care is high. In the US alone, the estimated number of individuals treated every year for DVT or pulmonary embolism (PE) is more than 600,000[2]. DVT and PE together may also cause more than 100,000 deaths in the US every year[3].

The market for antithrombotics includes drugs that affect the action of platelets and that are mainly used to prevent arterial thrombosis, e.g. the best-seller clopidogrel. Drugs that

1 Datamonitor 2009

2 Barclays Capital Equity Research, 2008
3 The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism, 2008

BioInvent is developing antibody drugs – the fastest growing segment of the pharmaceutical market with total annual sales of 40 billion USD.

affect the coagulation factors of the blood, and thereby prevent the blood from clotting, are mainly used in venous thrombosis. The annual global sales of this latter group of anticoagulants amounted to USD 6.7 billion in 2008 in the largest markets[4]. Anticoagulants currently available (mainly heparin substances) are inconvenient to administer and associated with a risk of bleeding. Better coagulants are therefore needed. In particular, drugs that are easier to administer (without the need for daily doses and frequent dose adjustment) would meet a significant medical need. The side-effect profile, in particular the risk of bleeding, is an important factor for new anticoagulant drugs. Various new anticoagulants that can be administered in tablet form instead of by injection are now in development. Two of these (rivaroxaban, dabigatran) have recently been approved for the prevention of thrombosis in patients undergoing major orthopaedic surgery. Other similar drugs are in late-stage clinical trials (e.g. apixaban, edoxaban) and may soon be out on the market. Several of these drugs are expected to become blockbusters, particularly those used for patients with atrial fibrillation.

The medical need for antithrombotics for patients who are immobilised is considerable. Patients may be bedridden for many reasons, e.g. cancer, stroke, coma, MS, infection, and where patients are old and weak. The treatments vary today, but often low molecular heparin is given and this must be injected daily during the treatment period. Estimates show that antithrombotic treatment of immobilised patients probably makes up an extremely significant percentage of the sales of low molecular heparin, which in 2009 amounted to USD 4 billion[5]. One study shown that these patients may be better off being treated with a commonly used anticoagulant over a prolonged period (up to 28 days) instead of 7 – 12 days, which is common now[6]. In other, presently ongoing studies, the prolonged treatment of these patients with newer anti-coagulants is examined.

The number of hip and knee surgeries in the major drug markets was estimated at around 2.4 million in 2009 and is expected to grow to around 3.1 million by 2015[7]. The market is dominated by low molecular heparin. Today heparin is injected daily for up to 15 and 30 days following knee or hip surgery. A prolonged treatment period can reduce the number of cases of deep vein thrombosis.

BioInvent expects TB-402 to have a product profile that is highly suitable for these patient populations because the antibody has a half-life that is believed to enable a single injection to be administered in connection with hospitalisation or surgery.

4 Datamonitor 2009

5 Datamonitor 2010
6 Ann Intern Med. 2010
7 Datamonitor 2008

Available clinical results have shown the product to be more effective in the prevention of thrombosis than the current standard treatment, enoxaparin. Clinical results also show that the product's effect can be reversed, which is desirable in case another surgery is needed. Another important benefit is that the function and metabolism of TB-402 are not affected by a patient's impaired liver or kidney function. The risk that TB-402 will have undesired interactions with other drugs is also thought to be small. These product properties can be expected to be particularly important in the case of older patients who are immobilised or who undergo hip or knee surgery, and who may be being treated with a number of other drugs or who often have organs with impaired function.

The market for antithrombotics for patients with atrial fibrillation is large and is currently dominated by warfarin (waran). Recently developed oral anticoagulants are expected to take a significant portion of this market in terms of value when they start to be sold over the next few years. TB-402, on the other hand, is expected to be administered by injection with long, i.e. monthly, intervals. An important benefit is that patients will probably not need to be monitored as is the case with current treatments. These product properties are expected to be particularly valuable for patients with atrial fibrillation who are hospitalised, old or suffer from dementia.

Cardiovascular diseases

Drugs for the treatment of cardiovascular diseases which include atherosclerosis, abnormal blood lipids, high blood pressure and diabetes, currently constitute the largest group of drugs and account for total sales of USD 90 billion in the seven largest markets alone[8]. This includes statins, which account for the largest portion in terms of value of the drugs used for the treatment of atherosclerosis.

BI-204 is being developed initially for a new market segment where there is a significant medical need – to prevent myocardial infarction or stroke in patients with acute coronary artery disease. The patient population for acute prevention, i.e. who are treated within 3 months following a cardiac infarction, is around 3 million[9]. Patients with acute coronary artery disease have a significantly elevated risk of complications and 30 percent suffer an additional infarction within three years. Current treatments such as statins, fibrates, niacin and cholesterol absorption inhibitors, have a limited effect on the fundamental course of the disease – the extensive atherosclerosis that is common in the blood vessels of these patients.

Drugs being developed for the treatment of atherosclerotic disease include phosphilopase A2 inhibitors (e.g. darapladib) HDL modifying drugs and CETP inhibitors (e.g. dalcetrapib, anacetrapib).

In addition to the large market for secondary prevention, BI-204 may be used for groups of patients with a significant risk of developing cardiovascular disease, such as individuals with insulin resistance and type II diabetes. This group of patients is very large and growing due to the age structure and lifestyle factors and patients are also often difficult to treat. The patients often develop metabolic syndrome[10]. BI-204's expected competitive advantage is based on its mechanism of action and effect on the fundamental course of the disease; it has in animal models been shown to reduce both the plaque volume in general and inflammation in the vessel walls and thereby stabilise unstable plaque.

Cancer

BioInvent has two product candidates in clinical development that are being developed to treat oncological diseases: TB-403 and BI-505.

TB-403 is a so-called angiogenesis inhibitor and has the potential to be used to fight several types of tumours. Its mechanism of action is general and kills tumours indirectly by blocking the blood supply to the tumour. This mechanism also means that TB-403 may be developed to treat other diseases outside of the field of oncology, e.g. certain eye diseases and inflammatory diseases.

The formation of new blood vessels is a process called angiogenesis. These newly formed vessels supply growing tissue with nutrients and transport waste away from the tissue. The formation of new vessels is essential for a tumour to grow, spread locally and metastasise. Tumours of a certain size are

8 Datamonitor 2009
9 Heart Disease and Stroke Statistics, 2007 Update
10 JAMA 2008, Kopprasch Diabetes 2002

BioInvent's product candidates are new innovative concepts to treat diseases where there is a great unmet medical need.

therefore dependent on the formation of new blood vessels to survive. Angiogenesis inhibition as a principle for cancer treatment has several advantages, e.g. the mechanism of action is different from other cancer therapies and it can therefore be useful in combination therapies. Interest in angiogenesis inhibitors in cancer treatment has increased significantly in recent years. These types of drugs have been shown to be effective in the treatment of a number of different types of cancer, e.g. kidney, colorectal, breast, ovarian and lung cancer as well as glioma. Drugs to treat each of these diseases have a sales potential of up to a few billion US dollars. One antibody, bevacizumab, has been approved for several of these indications and has quickly become a commercial success with sales approaching USD 6.0 billion in 2009.

Today the above-mentioned types of cancer are usually treated with different combinations of chemotherapy, radiation and surgery. Some forms of cancer are also sensitive to hormone therapy. Angiogenesis inhibitors work better in combination with current therapies. This is supported by clinical trials that have been conducted with other angiogenesis inhibitors in development and on the market. The effect of treatment has been proved to be additive or even synergistic in both treatment-naïve patients and in patients who have undergone several rounds of treatment. Angiogenesis inhibitors as a class of drug therefore have a broad area of application, because many forms of tumours are suitable for treatment with them and because a large percentage of patients are expected to benefit from the treatment.

TB-403 has a promising product profile with partially unique mechanisms of action; in addition to its direct angiogenesis inhibiting function, preclinical data shows that TB-403 inhibits the inflow of macrophages associated with tumours[11]. Macrophages are a type of cell believed to counter the effect of and contribute to the development of resistance to bevacizumab and other similar angiogenesis inhibitors. TB-403 may therefore be used as a single drug or in combination with bevacizumab to treat different patient groups including those who have developed resistance to or do not tolerate bevacizumab. Supporting preclinical data indicates that the effect of the two substances TB-403 may have an effect on tumours that do not respond to treatment with bevacizumab. Recently data was published in the renowned journal Cell supporting the fact that TB-403 is effective in several disease models and acts as an additive to bevacizumab[12]. Based on preclinical data and the mechanisms of action for TB-403, there are other reasons to expect that it will have fewer side effects such as gastrointestinal perforations, hypertension, and bleeding complications. It is therefore believed that TB-403 will be able to be used for the treatment of several solid tumours and thereby prolong disease-free survival and overall survival of these patients. It is also hoped that it will be possible in the future to expand beyond these indications.

BI-505 is the other product candidate BioInvent is developing for the treatment of oncological diseases. Unlike TB-403, it fights tumours directly by binding specifically to cancer cells and killing them through programmed cell death (apoptosis) and other direct effector mechanisms.

The first form of cancer for which BI-505 is being developed is the bone marrow disease multiple myeloma, a disease where there is a great medical need. BI-505 has been granted orphan drug designation in the US and the EU for this indication. This may give BI-505 market exclusivity as an antibody against the target protein ICAM-1 in these markets for up to ten years after market approval has been obtained.

11 Fischer et al Cell 2007

12 Van de Veire et al. Cell 2010

The medical need for improved treatments for multiple myeloma is significant. The average survival is 3 – 5 years and the progression of the disease is often painful because the tumour attacks bone tissue and the patients therefore often suffer from severe bone pain and bone destruction as well as neurological symptoms. These patients are also prone to infection and severe kidney damage. The number of new patients with multiple myeloma is estimated at 40,000 per year, while the number of patients with leukaemia is estimated at more than 200,000 per year.

Multiple myeloma is mainly treated today with chemotherapy and bone marrow transplantation. Notable among newer treatments is the proteasome inhibitor bortezomib and immunomodulating drugs such as lenalidomide and thalidomide. Sales of lenalidomide and bortezomib in 2009 amounted to around USD 3 billion[13] and sales of these drugs are expected to continue to rise sharply in the near future[14] because the medical need is still great. Drugs such as lenalidomide and bortezomib have improved survival somewhat in the hard to treat population of relapse patients, but the mortality rate remains high. At present there is a handful of new drug candidates in late clinical development phases that target myeloma. Some of these may obtain approval for clinical use over the next few years. Bevacizumab (anti-VEGF) and siltuximab (anti-IL6) are two interesting examples of biologics that are currently being tested in late clinical phases in myeloma patients.

BI-505 may have potential as a monotherapy for relapsed refractory patients with myeloma. These patients have been clinically proven to have elevated levels of target protein ICAM-1 in their tumours, a more serious disease and lower chance of survival[15] and ICAM-1 is believed to be involved in the occurrence and development of multiple myeloma[16]. The mechanism behind BI-505 makes it also conceivable that it may have the potential to be used in combination therapies with other anti-myeloma drugs and could therefore prolong survival in these patients. There is also a commercial opportunity in developing BI-505 as a treatment for other forms of tumours, such as lymphoma, stomach/intestinal, lung and breast cancer etc.

Competition

Traditionally, antibody-based drugs have mainly been developed by biotech companies. The company that sells the most antibody-based drugs is the US company Genentech, now part of Roche. Other biotech companies that have successfully launched antibody-based drugs include Biogen IDEC, Amgen and Alexion. In 2010 Amgen launched denosumab, an anti-RANKL antibody for the treatment of osteoporosis and bone metastasis in cancer patients, and this product is expected by analysts to be able to be sold for several billion US dollars per year. As antibody-based drugs demonstrate commercial success, interest from big pharma for these products increases. In addition to Roche, companies like Novartis, Johnson & Johnson (through its subsidiary Centocor), BMS (Medarex), AstraZeneca (MedImmune), Eli Lilly (ImClone), UCB and Abbott currently have products on the market and in late clinical development.

Several companies that are focusing on developing antibody drugs and antibody technologies have in recent years been acquired by larger companies. Companies that have not been bought, but belong independent, and that are developing antibody-based drugs include MorphoSys, Micromet, Regeneron, Ablynx, Immunogen and Seattle Genetics. Like BioInvent these companies enter into strategic development partnerships with large pharmaceutical companies where they utilise their expertise and technology within antibody development.

There are also other more product-oriented companies such as Genmab, Human Genome Sciences and Immunomedics which are successfully developing antibody drugs in late clinical phases. During the year the US company Facet purchased Abbott after a bidding war (USD 722 million, 67% premium). Another antibody company purchased in 2010 is Trubion (SEK 97 million, 50% premium).

13 MedTRACK database 2011
14 MedTRACK database 2011
15 Migkou et al. ASH poster 2009, Schmidmaier Int J Biol Markers 2006
16 Hideshima Nat Rev Cancer 2007

BioInvent's business model

BioInvent is developing innovative antibody drugs for the treatment of diseases where there is a significant unmet medical need. The goal is to generate value by building a sustainable portfolio of clinical development projects and, over time, commercialise several innovative drugs.

BioInvent's business model

BioInvent focuses on developing antibody drugs and documenting their biological activity and efficacy in clinical trials.

To be able to move the product candidates forward through late clinical development to full commercialisation, the Company works with major pharmaceutical companies such as Genentech and Roche.

In the case of certain projects, partnership agreements may be signed early on in the development phase, while other projects may be developed by the Company for a longer period. The timing of entering into partnerships is determined by costs, risk, the need for expertise and the additional value to be gained from continuing to develop the project in-house. The strategic purpose of the agreements is to ensure that the projects have the necessary expertise and resources to take the project to full commercialisation. To maximise the Company's potential to benefit from the overall value creation and provide the greatest possible flexibility, the Company will, in certain cases, also retain the market rights in individual geographical markets where the Company considers it feasible to establish a competitive commercial organisation. This strategy reduces business risk and can be adapted to market-specific and company-specific conditions. It also makes it possible to take maximum advantage of the growth in value of successful projects. The Company's ability to realise this strategy is supported by its ability to attract strong partners.

BioInvent has also entered into a number of development partnership where the development partner gains access to parts of BioInvent's antibody platform and antibody drug development expertise. This normally means that BioInvent or the partner, with the help of the n-CoDeR antibody library, identifies antibodies that bind to the target proteins that the partner has selected. The selected antibodies are then developed, either by the partner alone or within the framework of continuing cooperation with BioInvent. In this type of cooperation, the partner is responsible for all development costs and assumes all of the risk.

BioInvent's revenue model

According to BioInvent's business model, the Company receives income in the following ways:

- From a development partner when it buys in to the Company's projects.
- From customers for which BioInvent carries out development assignments.
- From customers that themselves are using BioInvent's technology (technology licenses).

Revenue flows come from:

- a cash payment when an agreement is signed.
- R&D milestone payments, i.e. payment when the project passes pre-defined milestones.
- when applicable, research financing.
- royalties, i.e. payments based on a percentage of end product sales.
- when applicable, revenues from the sale of products in the markets where the Company has retained the market rights or shares the market rights with a partner.

Today revenues consist of cash payments when contracts are signed, licence fees, milestone payments and research financing. In the longer term the goal is to ensure sustainable profitability through royalties and revenues from the company's own commercialisation in certain markets. Profits may be reported in individual years before this has happened when significant breakthroughs are made in one of our projects.

Projects ▶

Recruitment of patients is under way for the first study

BI-505



BI-505 (green signal) is binding to the cell surface of myeloma cells (red signal).

BI-505 is a fully human antibody binding to the adhesion protein ICAM-1 (CD54), a naturally occurring cell surface protein. Expression of ICAM-1 is elevated in a number of types of cancer, while it is low in most healthy tissue. In a first step, BI-505 is being developed for the treatment of multiple myeloma that expresses ICAM-1. BioInvent is developing BI-505 in-house.

Product characteristics

BI-505 is a specific antibody that binds to ICAM-1, with a high affinity. ICAM-1 is expressed by cancer cells in a number of types of cancer. The antibody induces programmed cell death (apoptosis) and mediates immune effector functions that also contribute to fighting and killing tumour cells.

Clinical need

In preclinical models, BioInvent has shown that BI-505 is especially effective against multiple myelomas that express ICAM-1. Multiple myeloma is currently mainly treated with chemotherapy and bone marrow transplantation. Notable among new treatments are the proteasome inhibitor bortezomib, and immunomodulating drugs such as lenalidomide and thalidomide. These drugs have improved survival somewhat in the hard to treat population of relapse patients, but mortality remains high. The average survival is 3-5 years for myeloma patients and the course of the disease is often painful since the tumour attacks bone tissue and patients suffer from severe bone pain and bone destruction as well as neurological symptoms. In addition, these patients are infection prone and may suffer from severe kidney damage.

Project status

A phase I study of the multiple myeloma indication was launched in the US at the beginning of 2010. The study is investigating safety, pharmacokinetics and pharmacodynamics to determine the optimal dose of the antibody for upcoming clinical phase II development. The study involves 30 – 40 patients who will be treated with intravenous doses of BI-505 every other week for a 28-day period with the possibility of extending the treatment until the condition deteriorates again. The study was expanded in August to include the University Hospital in Lund. Patients are now being recruited for the study from three clinics – two in the US and one in Sweden. The results of the study are expected to be able to be published in the second half of the year. BI-505 has been granted orphan drug designation both in Europe and the US for the multiple myeloma indication. This may give BI-505 market exclusivity for the treatment of multiple myeloma with an antibody against ICAM-1 for up to ten years after market approval has been obtained.

Patent protection

BioInvent has applied for patents for antibodies against ICAM-1 and their ability to induce apoptosis in various types of tumours such as multiple myeloma, lymphoma and carcinoma.

FDA approval to start phase II studies

BI-204

BI-204 targets oxidised forms of apoB100, a lipoprotein that is part of the LDL particle. Research in recent years has shown strong links between oxidised LDL and harmful inflammation of the vessel walls. This type of inflammation leads to the formation of atherosclerotic plaque that may fragment and cause blood clots. The mechanism of action supports the idea that BI-204 can be developed as a treatment for atherosclerosis to reduce the occurrence of myocardial infarction in high-risk patients. These are primarily patients with coronary artery disease (CAD), especially individuals who have already suffered a myocardial infarction.

BioInvent has entered into a strategic partnership with Genentech where the companies are jointly developing and commercialising BI-204. Under the agreement the companies have joint responsibility for clinical development. Genentech has licensed the North American commercialisation rights, while BioInvent has retained the rights for the rest of the world.

Product characteristics

BI-204 has the potential to stabilise plaque at risk of fragmentation, and may also reduce its size. BI-204 therefore has the potential to attack the underlying cause of coronary artery disease – the extensive atherosclerosis that is common in these patients. An important component in this disease is believed to be harmful inflammation in the patients' blood vessels. BI-204 has been shown to modulate this process in the vessel walls by the antibody binding to the oxidised LDL. Links have been shown between these oxidised forms of LDL and the inflammatory processes that lead to plaque formation in the vessel walls.

Preclinical trials support the idea that the mechanism behind BI-204 is modulation of the inflammatory processes with a reduction of pro-inflammatory cells in the plaque as a result, which in turn reduces the formation of new plaque and reduces existing plaque.

Clinical need

The goal is for BI-204 to be able to prevent myocardial infarction in patients with acute coronary artery disease. These patients have a substantially higher risk for complications; 30 percent have another myocardial infarction within three years. Currently no effective drugs are available that have a significant effect on the underlying cause of the disease – the extensive atherosclerosis that is common in the vessels of these patients.

There is a significant medical need for new treatments for atherosclerosis that can stabilise plaque at risk of fragmenting, and hopefully also reduce its size. Since a drug of this kind would have great commercial potential, considerable research initiatives are under way in this field.

Clinical observations show that metabolic syndrome, like the syndrome components insulin resistance and hyperglycaemia, are more common in individuals with high concentrations of oxidised LDL. Thus BI-204 may add to the treatment of patients with type 2 diabetes and metabolic syndrome.

Alliance with Genentech

In January 2007 the Company entered into a strategic partnership with Genentech Inc. to develop and commercialise BI-204. Genentech made a cash payment to BioInvent of USD 15 million. An additional USD 15 million will be paid when the first patient in the phase II study has received the first dose. In the partnership with Genenetech, BioInvent may receive up to USD 190 million in cash payments as well as royalties on sales in North America.

Under the agreement Genentech and BioInvent will be jointly responsible for clinical development. Genentech will be responsible for, and will have sole control of, all commercialisation of the drug in North America, while BioInvent will be responsible and will have sole control of, commercialisation in the rest of the world. During the development period Genentech and BioInvent will share the development costs according to an undisclosed split.



An image of plaque in a mouse shows high macrophage infiltration (green signal).

Project status

In November 2010 the US Food & Drug Administration (FDA) granted approval for the launch of a phase II study for BI-204. The study is a randomised, placebo-controlled, double-blind, multicentre study where BI-204 will be administered intravenously to patients on standard-of-care therapy for stable coronary artery disease. The study is designed to demonstrate a significant reduction in inflammation in the blood vessels affected by atherosclerosis. The trial will enrol 120 patients with stable coronary artery disease in centres in the United States and Canada. Results from the study are expected to be reported in the first half of 2012.

Patent protection

The oxidised forms of the apolipoprotein apoB-100 that cause harmful inflammation within the vascular wall, the use of these in drug development, products aimed at these target proteins, the mechanisms of action, as well as the formulation of BI-204 are patent pending in about 40 countries, including major markets such as the United States, Europe, Canada, Japan, Australia, China and India. Patents have been granted in the US and Europe among other places.

Strong phase II data reported

TB-402

TB-402 is a human monoclonal antibody targeting coagulation Factor VIII. The product is intended to be an anticoagulant to prevent deep vein thrombosis in orthopaedic surgery and to prevent stroke in patients with atrial fibrillation. TB 402 is being developed in collaboration with ThromboGenics.

Product characteristics

TB-402 effectively inhibits thrombosis by binding to Factor VIII which is essential for the coagulation of the blood. It is important that the inhibition of factor VIII will be controlled and not give rise to unwanted bleeding. In clinical studies, TB-402 has shown a significantly better anticoagulant effect than the current standard treatment.

The prolonged half-life of TB-402 reduces the need for maintenance treatment compared to other anticoagulants and is therefore believed to be easier to administer than current treatments available today.

Clinical need

Several patient groups, such as patients who are immobilised due to medical treatments or patients who undergo major orthopaedic surgery, are in great need of safe and improved anticoagulant therapy. If they are not treated, these patients risk deep vein thrombosis.

Current treatments, such as various heparin drugs, require daily injections or sometimes lead to severe bleeding. It is therefore particularly important for new anticoagulant drugs to have a good side-effect profile with respect to the risk of bleeding. The mortality rate of patients affected by deep vein thrombosis is high and the costs for society relating to patient healthcare needs and subsequent long-term follow-up care is great. Another group requiring effective antithrombotic treatment consists of patients with atrial fibrillation who may suffer from complications such as stroke.

In contrast to currently available treatment, TB-402 is expected to be administered as a single dose in connection for example in immobilised or surgically treated patients, or with intervals of up to two to four weeks for chronic conditions. The benefits of this approach are patient convenience and compliance. The treatment is also expected to be associated with a low risk of bleeding and other side effects such as liver or kidney toxicity. The need for patient monitoring is not expected to be significant.

Alliance with ThromboGenics

BioInvent and ThromboGenics Ltd entered into an alliance in September 2004 for the joint development of antibody-based drugs to treat vascular diseases. Under the alliance the expertise of both companies is combined for the discovery, development and production of antibodies. BioInvent is contributing knowledge and experience in antibody development, production and immunology, and ThromboGenics is contributing expertise in research and clinical development in the area of vascular medicine. The partnership covers both TB-402 and TB-403.

Project status

A clinical phase II study of TB-402 was reported in May 2010 showing that the antithrombotic effect of TB-402 is clearly better than that of the comparative drug enoxaparin. The study was conducted in patients who had undergone knee replacement surgery.

The phase II study was an active (enoxaparin)-controlled, dose-escalating, prospective, randomised, open multicentre study involving 316 patients at 30 clinics, mainly in Europe. All patients received 40 mg of enoxaparin preoperatively. Following surgery the patients were randomly divided into two groups and received either TB-402 or enoxaparin. TB-402 was administered as a single injection 18 – 24 hours after surgery, while enoxaparin was administered in the form of subcutaneous injections once a day for a period of at least ten days. Patients treated with TB-402 showed a statistically significant lower instance of venous thrombosis than patients who were treated with enoxaparin*. The study also showed that TB-402 and enoxaparin have similar safety profiles.

Results reported earlier from the phase I study confirmed that the antibody provides a beneficial partial inhibition of Factor VIII with a plateau effect in higher doses as shown previously in preclinical studies. A stable and long-acting anticoagulant effect was also demonstrated.

* A pooled analysis showed that the frequency of venous thrombosis was 22% for patients treated with TB-402, compared to 39% for patients treated with enoxaparin. This was a statistically significant difference. The complete study was recently published (Verhamme et al., 2011, J Thromb Haemost.).



Erythrocytes in fibrin network

Two interaction studies of TB-402 have also been conducted. One of the studies showed that the effect of TB-402 could be reversed by giving the target protein (Factor VIII) that TB-402 blocks. Another study showed that TB-402 was safe and well tolerated in patients with DVT who received the standard treatment (enoxaparin and warfarin).

The strategy is to apply for market approval for TB-402 that will cover its use in both knee and hip surgery. A phase IIb study for the prevention of venous thromboembolism (VTE) following hip surgery is now being prepared.

Patent protection

Antibodies that only partially inhibit Factor VIII, pharmaceutical preparations containing such antibodies and their use in drug development are all patent pending in markets such as Europe, Japan, Canada, the United States and Australia. A patent has been granted in Europe and Japan among other places.

Phase II are about to be started

TB-403

TB-403 is a monoclonal antibody targeting PIGF, a protein that affects the development of new blood vessels (angiogenesis). The project is being developed primarily to treat types of cancer that are dependent on the growth of new blood vessels. TB-403 was originally developed within the framework of BioInvent's strategic partnership with ThromboGenics. In June 2008 the Company entered into a strategic product alliance with Roche. This gives Roche exclusive, worldwide rights to develop and commercialise TB-403 at the same time as BioInvent and ThromboGenics retain a right to market the product in the Nordic, Baltic and Benelux countries. Roche is currently financing the development of TB-403.

Product characteristics

TB-403 is a new form of angiogenesis inhibitor that is specific to the PIGF target protein. PIGF is often upregulated in cancer and chronic inflammatory conditions. This makes it a suitable target protein in the treatment of these diseases. PIGF stimulates the formation of new blood vessels like the vascular endothelial growth factor ("VEGF"), but unlike VEGF, PIGF is not believed to affect the patients' physiological, normal angiogenesis. TB-403 can therefore be expected to have a favourable side-effect profile.

When patients are treated with other angiogenesis inhibitors, an upregulation of PIGF is sometimes observed. It is likely therefore that PIGF plays a role in the body's adaptive reaction, which in turn may cause resistance to these drugs. BioInvent therefore believes that TB-403 should be able to reinforce the effect of these angiogenesis inhibitors and further be an effective supplement to chemotherapy. The antibody also has the potential to be used in patients who has developed resistance to VEGF inhibitors.

There is also preclinical data to suggest that the risk of developing resistance is lower in treatment with PIGF inhibitors than treatment with VEGF inhibitors.

Clinical need

Cancer constitutes a heterogeneous group of diseases, which complicates the development of drugs directed at tumour cells with the intention of killing them. A new and attractive strategy is to attack the tumours indirectly by blocking the growth of new blood vessels. These blood vessels supply growing tissue with nutrients and transport waste away from the tissue. Tumours over a certain size are dependent on the formation of new blood vessels in order to grow and survive. A substance that inhibits the growth of new blood vessels could therefore reduce tumour growth and increase the patient's chances of survival.

Current treatment for these types of cancer usually includes various combinations of chemotherapy or radiation, as well as surgery. Certain types of cancer are also sensitive to hormone therapy. Angiogenesis inhibitors work better in combination with currently available treatments. This is supported by clinical trials that have been conducted with other angiogenesis inhibitors under development and on the market. The effect of the treatment has been shown to be additive or even synergistic, both among patients who recently began treatment and in patients who received several rounds of treatment. Therefore as a class, angiogenesis inhibitors have a broad spectrum of application, in part because a large percentage of patients are expected to benefit from the treatment.

Alliance with Roche

In June 2008 BioInvent and its partner ThromboGenics entered into a strategic licence agreement with Roche for development and commercialisation of TB-403. Roche paid BioInvent and ThromboGenics a cash payment of EUR 50 million in July 2008.

In January 2009 the transfer and implementation of technology and process development to Roche for ongoing clinical development of TB-403 were successfully concluded and an additional payment from Roche of EUR 5 million was received by BioInvent and ThromboGenics.

Roche initiated during 2010 an imaging study on patients with metastasing, treatment resistant colorectal and ovarian cancer. BioInvent and its development partner ThromboGenics accordingly received a milestone payment of EUR 10 million from Roche. The study was finished later during the year in accordance with the study protocol.

If successful development and commercial milestones are reached, BioInvent and ThromboGenics stand to receive an additional EUR 435 million in milestone payments and a double-



Antibodies against PIGF bind strongly to the vessel walls of capillaries in the human placenta.

digit percentage of sales of TB-403 in royalties and any back-up programmes based on inhibition of PIGF.

Roche received a global licence with soles rights to develop and commercialise TB-403. ThromboGenics, which discovered TB-403, will receive 60 percent and BioInvent 40 percent of the revenues from Roche.

BioInvent and ThromboGenics have retained a right to market the drug in the Nordic, Baltic and Benelux countries. Roche is responsible for all development costs.

Project status

Phase II clinical trials is expected to be initiated by development partner Roche during the first quarter of 2011. The first phase II study is a combination study with bevacizumab (Avastin, Roche) in patients with the brain tumour glioblastoma multiforme.

Patent protection

Patents that cover treatment with antibodies against PIGF for the purpose of reducing or preventing pathologic angiogenesis, vascular leakage, pulmonary hypertension, cancer and inflammation, have been granted in Europe. In the US similar patents have been granted for the treatment of pathological angiogenesis and patents applications for other indications are being processed. An objection has been filed against the European patent. The objection was rejected in the court of first instance. In addition, patent applications for TB-403 and similar antibodies have been filed in Europe, Japan, Canada, the US, Australia and several other countries.

Preclinical research

BioInvent's preclinical research is currently focused on oncology and inflammation. By using the Company's key compentence and through select alliances with internationally recognised academic teams and industrial partners, such as ThromboGenics and Human Genome Sciences, the Company has built up expertise in fields such as cancer biology, angiogenesis, tumour immunology, acute and chronic inflammatory diseases and immunology.

Over the past decade BioInvent has accumulated a substantial amount of experience using the most relevant disease models in these fields. These models are used to identify the most effective and potent antibody candidates, while extensively investigating the expected safety and tolerability of the antibody, based on the biology of the disease and the mechanism of action of the antibody.

The Company's preclinical research is aimed at building a portfolio of drug candidates. This research is supplemented by select research collaboration with large pharmaceutical companies, giving these companies access to BioInvent's technology for the production of product candidates. These alliance programmes involve little risk for BioInvent and provide an opportunity to earn revenues in the future in the form of milestone and royalty payments.

BioInvent's research

BioInvent's strategy for research and development is to produce antibody-based drugs and document their biological effect in clinical research.

In order for the product candidates to advance through late clinical development towards full commercialisation, BioInvent works with large pharmaceutical companies. In certain projects a partnership agreement is signed early on in development, while other projects may be developed for a longer period by the Company.

BioInvent is aiming to broaden and expand its portfolio of drugs to give the Company several opportunities to successfully develop new products and thereby increase the likelihood of commercial success.

So far the Company has mainly launched projects in alliances with external research teams, either in academic environments or in industry. These research teams not only contribute target proteins, but also significant biological and medical expertise. The Company continues to place great emphasis on cooperation with external research teams as an important source of new medical concepts. Partnerships with leading Swedish and internationally academic groups have been initiated during 2010 with the intent to develop antibodies to treat severe leukaemia and solid cancers, based on e.g. the role of cancer-associated fibroblasts in tumour development.

As the Company matures and its expertise in individual areas increases, medical concepts from internal research programmes is launched. BI-505 for the treatment of multiple myeloma is the result of one such programme. The functional screening system (F.I.R.S.T.) developed by BioInvent which identified this candidate is a platform for further research programmes.

F.I.R.S.T.: Combined discovery of target protein and antibody

BioInvent has developed a method known as F.I.R.S.T. which makes it possible to directly detect new drug candidates without prior knowledge of the target proteins of the antibodies. The method is based on isolating antibodies from the n-CoDeR antibody library that selectively bind to one cell population (or other complex collection of target proteins) in preference to another.

BioInvent has a strong technology platform for developing and manufacturing antibody-based drugs. The Company's research focus is inflammation and cancer.

This is achieved by screening antibodies, step-by-step, that bind to one cell population over the other population through so-called differential screening. Identified antibodies are then selected based on their functional properties.

The advantage with this method is that it is possible to detect antibodies that bind to a target proteins which was previously not known to be linked to a specific effect, such as initiating the death of a tumour cell. Another advantage with this method is that antibodies are identified as they bind to target proteins found in their natural environment (e.g. the cell surface), which increases the probability that the antibodies will mediate the desired effect when administered as a medication in vivo. The method also makes it possible to find antibodies that bind to target proteins which are in a relative state of surplus or deficit, irrespective of whether this is due to differences in protein expression, or if disease-associated epitopes that arise in other ways are exposed on the target cell.

BioInvent has used this method to identify antibodies that bind specifically to cancer cells and which, when they bind to their target protein, initiate cell death through various mechanisms. Consequently, antibodies with a direct therapeutic effect are identified in a single step. This method was used to identify BI-505, the Company's product candidate for the treatment of haematological cancer such as multiple myeloma. With the help of the F.I.R.S.T. method, BioInvent is actively seeking new drug candidates to treat haematological cancers.

Product partnerships

One way of gaining access to promising target structures and projects is to enter into partnerships with companies that have assets and competence that complement those of BioInvent. BioInvent's aim is for these strategically important product partnerships to be characterised by balanced and equal ownership and resource allocation between the partners. BioInvent currently has two such product partnerships – one with ThromboGenics in vascular diseases (including TB-402 and TB-403), and a recently initiated collaboration with Human Genome Sciences within inflammatory diseases.

Research partnerships

BioInvent has entered into a series of partnerships to develop and manufacture antibodies. In these partnerships, BioInvent received one-off payments and research support, as well as future rights to milestone payments and royalties on sales of products from the partnerships. A number of the current partnerships are described below:

- **Bayer HealthCare:** Identifying and developing antibody-based products with the help of the n-CoDeR library. The agreement covers the development of up to 14 antibody-based products.
- **Daiichi Sankyo:** Licence and research agreement for the development of therapeutic antibodies targeting several target proteins with the help of the n-CoDeR library. The agreement gives BioInvent certain rights to market products in Scandinavia and the Baltic region.
- **Mitsubishi Tanabe:** Identifying and developing antibody-based products with the help of the n-CoDeR library. The agreement covers development of up to five antibody-based therapeutic products.

BioInvent has also been manufacturing materials for several years for clinical studies for a number of customers.

Human antibody technology

BioInvent develops therapeutic, fully human, monoclonal antibodies using the Company's own n-CoDeR platform. Monoclonal means that all antibody molecules in a given drug are exact copies of each other. This simplifies characterisation of the product and the manufacturing process and makes the biological effect of the drug more precise and predictable. One important reason why antibodies are so effective as pharmaceuticals is that they comprise a natural part of the organism's defence against diseases. Therefore they have naturally evolved to be specifically targeted and cause an appropriate biological reaction as they bind to their target protein. This activates the immune system's effector functions, a collective term for a host of different reactions of the body's defense system with the purpose of neutralising the threat by initiating the antibody binding reaction. Since this is a very precise reaction, it is important for the antibody drug that is introduced to be as similar to the body's own antibodies as possible.

The first generation of monoclonal antibody-based drugs came from animals, primarily mice. These mouse antibodies, with components that were foreign to the human immune system, triggered an immune response to the introduced antibodies. Later, in the mid-1990s, genetic engineering made it possible for these mouse antibodies to become more similar to those found in humans. Several such "chimeric" antibody-based drugs (e.g. rituximab) are currently approved and widely used. The "humanised antibodies" (e.g. bevacizumab) represent a further improvement; although still derived from mice, they appear more human-like to the immune system. The final link in this chain of development is to introduce fully human antibodies.

There are currently two fundamental technologies for manufacturing human antibodies. One involves genetic manipulation of mice, in which the mouse genes for antibody production are replaced by the corresponding human genes, resulting in a genetically altered mouse capable of producing human antibodies directly. The second technology involves creation of "antibody libraries" in test tubes containing human antibodies, which can then be used to produce fully human antibodies.

There are different ways of designing an antibody library. Important parameters that determine library quality include size, variability and stability and functionality of the produced molecules. These factors determine the likelihood of finding an antibody with the desired binding properties against all types of target proteins.

n-CoDeR antibody library

BioInvent has developed a powerful technology platform for discovery, development and production of human antibodies. The n-CoDeR antibody library is the source of the Company's drug candidates. The antibody-library is the cornerstone of BioInvent's technology platform. The library contains a collection of more than 20 billion human antibody genes that are stored within bacteria in test tubes. The bacteria act as production units for the antibodies making it possible to search through the library to identify precisely those antibodies that bind to a specific target protein. The n-CoDeR library is searched using an established technology called phage display. To identify the optimal antibody, BioInvent has developed automated processes in which robots carry out the analysis on an industrial scale. The n-CoDeR library consists of naturally occurring antibody genes. Every component comes from nature, but the combinations are largely new, making it possible to build an antibody repertoire that is greater than nature's own variability. BioInvent calls this "evolution beyond nature." The n-CoDeR library is protected by patents and patent applications in the largest markets.

Fully human antibodies can quickly be retrieved from the n-CoDeR antibody library to develop the Company's drug candidates.

Financial information ▶



Directors' report

The Board of Directors and the CEO of BioInvent International AB (publ), co. reg. no. 556537-7263, hereby present the annual accounts and consolidated accounts for the financial year 1 January–31 December, 2010. The Company is registered in Sweden and is located in the Lund municipality. The visiting address is Sölvegatan 41, Lund and the postal address is 223 70 Lund. The descriptions below of the status of BioInvent's projects are current at the time this annual report was presented.

Operations

BioInvent, listed on the NASDAQ OMX Stockholm (BINV), is a research based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects mainly within the areas of thrombosis, cancer, atherosclerosis and inflammation.

Development projects

BioInvent is currently running four projects in the development phase. In the development phase the safety profile of the product candidate is tested in animal models, before testing safety and efficacy in clinical trials.

Thrombosis (TB-402)

TB-402 is a human antibody binding to Factor VIII. The antibody has shown a beneficial partial inhibition of Factor VIII. The objective is to initially develop a drug that prevents deep vein thrombosis following orthopaedic surgery. Deep vein thrombosis caused when a blood clot forms in a deep vein, most commonly in the deep veins of the lower leg. Deep vein thrombosis is a major public health issue and it is estimated that in the US alone, more than 600,000 individuals are affected by deep vein thrombosis or pulmonary embolism each year. The number of patients undergoing total hip or knee replacement is estimated at around 2.4 million in 2009 and is expected to grow to approximately 3.1 million 2015 in the seven major pharmaceutical markets. Patients undergoing hip replacement or knee surgery are particularly at risk of developing deep vein thrombosis and all patients are therefore treated with anticoagulants prophylactically in order to reduce the risks of blood clots. TB-402 is a long-acting agent, which means it could be given as a single dose to prevent the development of deep vein thrombosis in patients undergoing surgery. This simple approach to prophylaxis would be an attractive option, as all current anticoagulant treatment options require daily treatment for up to several weeks. The project is carried out within the alliance with ThromboGenics.

Results from the phase I trial show that TB-402 is both safe and well-tolerated. No serious adverse events related to TB-402 were reported. The pharmacokinetic analysis undertaken as part of the phase I trial confirm a prolonged half-life of approximately three weeks. Additional studies have shown that the effect of TB-402 can be reversed by giving the target protein (Factor VIII) that blocks TB-402 and also that TB-402 is safe and well tolerated in patients that are given standard treatment (enoxaparin and warfarin) for deep vein thrombosis.

Results from a phase II trial for the prevention of venous thromboembolism following orthopaedic surgery, were reported in May. The phase II results showed the superior antithrombotic activity of TB-402, when compared to enoxaparin (Lovenox®: sanofi-aventis). The study showed that the two drugs had comparable safety. Enoxaparin is currently the standard treatment to prevent venous thromboembolism in this setting. Venous thromboembolism encompasses both deep venous thrombosis and pulmonary embolism.

The phase II trial was a multicenter, dose-escalating, randomised, open-label trial, evaluating TB-402 against enoxaparin for the prophylaxis of venous thromboembolism after knee surgery. All patients received enoxaparin 40 mg pre-operatively. Post operatively, patients were randomized in a sequential cohort design to one of three doses of TB-402 (0.3 mg/kg, 0.6 mg/kg or 1.2 mg/kg) or enoxaparin 40 mg (3:1; n=75 per group).

TB-402 was administered as a single intravenous bolus injection 18–24 hours after orthopaedic surgery, whereas enoxaparin was given as a 40mg subcutaneous injection every day for a period of at least 10 days. The primary effect parameter was evaluated on days 7 – 11 and based on measurements of symptomatic and asymptomatic cases of venous thromboembolism with the help of venography. The primary safety endpoint was the number of patients with major or clinically relevant non-major bleeding from randomisation until the end of the study at 3 months. The study enrolled a total of 316 patients across 30 centers in Europe.

A pooled analysis of all groups treated with TB-402 and the group treated with enoxaparin showed a statistically significant reduction of the incidence of total venous thromboembolism. The study also showed that TB-402 and enoxaparin had a similar safety profile. The results were presented on 8 July at the 21st International Congress on Thrombosis in Milano.

The strategy is to apply for marketing approval for TB-402 covering the use for both knee and hip surgery. A phase IIb study for the prevention of venous thromboembolism following hip surgery is currently being prepared.

Atherosclerosis (BI-204)

The product candidate BI-204 targets oxidized forms of the LDL cholesterol (oxLDL). Links have been shown between oxidized forms of certain lipoproteins and the inflammatory processes that lead to plaque formation in the vessel walls. BI-204 has in preclinical studies reduced inflammatory processes and plaque formation significantly. The results also show a considerable reduction in the size of existing plaques in animals treated with BI-204. Results supports that the mechanism behind BI-204 is a modulation of the inflammatory process resulting in a reduction of pro-inflammatory cells in treated plaques, which in turn leads to a reduction in new plaque formation and the regression of existing plaques. It is being developed as a drug for the prevention of secondary events in patients with cardiovascular disease. In a population-based, prospective, observational study of the risk of development of metabolic syndrome (JAMA. 2008; 299 (19) 2287-2293) higher concentration of oxidized LDL was associated with increased incidence of metabolic syndrome overall, as well as its components of insulin resistance and hyperglycemia. These observations support the picture that oxidized LDL can be an important target structure for developing new medications to treat patients with type 2 diabetes and metabolic syndrome. BI-204 is developed in collaboration with Genentech, a wholly-owned member of the Roche Group.

The phase I programme was completed in 2009. The study was a double-blind, within-group randomised dose-escalation trial testing both single and multiple doses of BI-204 administered either intravenously or subcutaneously. In total, 80 healthy male or female subjects with elevated levels of LDL cholesterol were included in the trial. BI-204 was well tolerated and pharmacokinetic results showed the halflife was in the expected range for fully human antibodies.

In November 2010 the US Food and Drug Administration (FDA) approved BioInvent's plan for the first Phase II study for BI-204. The phase II study is a randomised, placebo-controlled, double-blind, multicentre study of BI-204, which will be administered intravenously to patients on standard-of-care therapy for stable atherosclerotic cardiovascular disease. The trial is designed to demonstrate a significant reduction in plaque inflammation following treatment with BI-204 measured with FDG-PET (18F 2-deoxyglucose positron emission tomography). The trial will enrol 120 patients with stable coronary vascular disease in centers in the United States and Canada. BioInvent will receive USD 15 million in milestone payments when the first patient is dosed, which is expected to take place soon. Results from the study are expected to be reported in the first half of 2012.

Cancer (TB-403)

The product candidate TB-403, is a monoclonal antibody that blocks tumour angiogenesis, the development of new blood vessels, which is required for tumour nutrient and oxygen supply supporting tumour growth. By blocking angiogenesis, tumour progression and metastasis is prevented. TB-403 is directed against the placental growth factor, PlGF, secreted by tumours and specifically over expressed in cancer and chronic inflammatory conditions. It affects the formation of new vessels in tissue that is under stress. Normal vasculature is not dependent of PlGF. Mice lacking PlGF are healthy and reproduce normally. Hence blocking PlGF is expected to be a relatively safe and well tolerated anti-angiogenic treatment. TB-403 has been shown to inhibit tumour growth in animal models.

Up to June 2008 the project was carried out within the alliance with ThromboGenics. In June 2008 BioInvent and partner ThromboGenics entered into a strategic license agreement with Roche for development and commercialisation of TB-403. Roche received a worldwide, exclusive license to develop and commercialise TB-403. BioInvent and ThromboGenics retained co-promotion rights for the product in the Nordic, Baltic and Benelux regions.

The first phase I study in 16 healthy male subjects showed that TB-403 is safe and well tolerated. A follow-up study in patients with advanced cancer was presented in November 2009 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, U.S.. TB-403 was shown to be well tolerated and no dose limiting toxicity was observed with doses up to 10 mg/kg weekly and 30 mg/kg every three weeks. In this patient population with advanced solid tumours, stable disease was observed in six of 23 patients whereof two patients had stable disease in 12 months. A DCE-MRI imaging study of TB-403 that was commenced by Roche earlier this year has been terminated. Results from initial test cohort did not support continuation of the study as per protocol.

Roche plans to begin the next phase of the development in Q1 2011 with two studies. A phase Ib/II trial of TB-403 in combination with Avastin in patients with an aggressive form of brain tumour (Glioblastoma multiforme) and a phase Ib trial of TB-403 in combination with sorafenib in patients with liver cancer (Hepatocellular carcinoma). The glioblastoma study will examine the safety and clinical effect of TB-403 in combination with Avastin. The study will consist of two parts and will include 80 patients. The first part will identify a safe dose of TB-403 to be combined with Avastin, and this will then be used in the second, clinical effect part of the study where progression free survival will be determined. The phase Ib study of liver cancer will also have a dose-determination part for safe TB-403 dosing in combination with sorafenib and a more explorative part where the safety, pharmacokinetics and pharmacodynamics of the combination will be studied. The study will include 60–70 patients.

Cancer (BI-505)

The drug candidate BI-505 is a human antibody that targets the adhesion protein ICAM-1 (also called CD54). In tumour cells the expression of ICAM-1 is elevated and it is therefore a candidate for being a suitable target protein for a therapeutic antibody. In addition to inducing apoptosis the antibody also provides important immuno-effector functions that help to kill tumour cells. BI-505 has in different animal models proved to be very effective at killing tumours and more effective than existing drugs.

BioInvent's intention is, in an initial stage, to treat patients with multiple myeloma. Other forms of haematologic cancer may also become relevant as indications. The possibility of treating ICAM-1 expressing solid tumours will also be examined further in additional preclinical trials. The number of newly diagnosed patients with multiple myeloma is more than 40,000 per year and the number of newly diagnosed patients with blood cancer is more than 200,000 per year.

BI-505 has been granted orphan drug designation in the United States and Europe for the indication of multiple myeloma. This status gives BI-505 possibility for market exclusivity for treatment of multiple myeloma with an antibody against ICAM-1 for up to 10 years after marketing approval is obtained.

A phase I study for the treatment of multiple myeloma was launched in the US at the beginning of the year. The study will investigate safety, pharmacokinetics and pharmacodynamics and will aim to define the optimal dose of the antibody for upcoming clinical phase II development. The study will involve 30 – 40 patients. The patients will be treated with intravenous doses of BI-505 every other week for a 28-day period with the possibility of extending the treatment until the condition deteriorates again. The study was expanded in August to include University Hospital in Lund. Three clinics – two in the U.S. and one in Sweden – are now recruiting patients for the study. Dosing of patients in dose cohort seven of the planned nine cohorts has recently started.

Research projects

BioInvent is running a number of projects in the research phase i.e. the stage prior to selection of a Candidate Drug. The Company's research portfolio currently includes projects mainly within the areas of cancer and inflammation. In the area of cancer, the research is focused on programmed cell death inducing antibodies with a strong ability to kill tumour cells, as well as activation of the body's own immune defence cells. BioInvent is also working in cooperation with a leading academic team in the UK on the possibility of using new therapeutic antibodies to strengthen these mechanisms of action and the effect of already approved and clinically well-tolerated therapeutic antibodies. With BioInvent's F.I.R.S.T. platform, where antibodies are identified directly based on their powerful ability to kill primary cancer cells through differentially expressed, cancer cell-associated surface receptors, the Company is looking for new drug candidates for the treatment of various haematological cancers. The cooperation with leading Swedish and international academic teams was initiated with the objective to develop antibodies for the treatment of serious haematological and solid cancers through new pharmaceutical concepts based, for example, on the role of cancer-associated fibroblasts in tumour growth.

The Company's inflammation research is being enhanced by a partnership entered into in March 2010 with the US company Human Genome Sciences. Under this partnership the companies will work together to develop and commercialise antibody-based drugs based on target proteins from Human Genome Sciences' research and BioInvent's antibody technology. The Company's initiatives in oncology and inflammation have in common the development of therapies that impede the functions and activity of myeloid cells.

BioInvent has initiated a new project in cooperation with a leading academic group for the treatment of type I diabetes.

The Company is also conducting research and development on antibody-based drugs in cooperation with other external partners. Such partners include Bayer HealthCare, Daiichi Sankyo and Mitsubishi Tanabe. All in all BioInvent has entered into agreements of this kind with the possible development of up to 30 antibody-based products. As well as undisclosed license fees and research funding, BioInvent will receive milestone payments and royalties on sales of any products commercialized.

Personnel and organisation

All research and development is conducted in project format with a matrix containing the following main areas:

The preclinical department is mainly responsible for discovering new product candidates.

The groups working in protein technology and pharmacy are responsible for developing the cell lines that will produce the products and for other process development, as well as for all production, characterisation and quality control of the products in compliance with directives from authorities.

The Clinical department is responsible for preclinical safety tests and clinical development of the Company's product candidates, as well as for ensuring that the Company's drug development is carried out in compliance with pharmaceutical legislation. The activities within this unit's area of responsibility are largely outsourced to external contract research organisations.

In addition to the line functions referred to above, the Company's quality assurance department and the Company's own patent department are directly involved in research and development.

As of 31 December 2010 BioInvent had 92 (105) employees, 77 (89) of whom work in research and development. About 90 percent of the Company's employees have university degrees, including 40 percent with PhDs.

Total absence due to sickness decreased compared with 2009. Long-term absence and short-term absence decreased somewhat. Sickness absence and other key figures can be seen in note 1.

Environment

BioInvent places great importance on environmental work which is an integrated part of the daily routines. BioInvent works actively with environmental issues and the principles under the general rules of consideration in the Swedish Environmental Code are observed in the Company's ongoing operations. The Company consistently endeavours to reduce the use of substances that may be harmful to the environment and ensure that environmental impact is kept to a minimum. The aim is to assess the possibility early on in the value chain of replacing a substance that is harmful to the environment with a less harmful one. Another goal is to continuously improve the use of chemical substances and other resources so that the Company's environmental impact is minimised in this respect as well. Proactive environmental efforts reduce the risk of harming the environment and health and put the Company in a better position to handle future environmental legislation and societal requirements.

BioInvent has a permit in accordance with the Swedish Environmental Code for manufacturing of biological pharmaceutical substances. The Group's operations require permits according to the Swedish Environmental Code, and reports are required to be submitted to Lund municipality. Selfmonitoring is carried out to monitor the Company's operations on an ongoing basis to counteract and prevent negative environmental impact. As part of this self-monitoring process, the Company has introduced a description of environmental consequences and a plan for the self-monitoring process.

The Company has limited emissions from its laboratories and production facility. The emissions consist of commonly found salts and easily biodegradable organic substances. Waste is sorted and separated, and special procedures are applied for handling environmentally hazardous waste.

The processes of developing, manufacturing and distributing pharmaceutical substances are becoming more and more complex and require energy. Like most other companies, BioInvent's emissions are largely the result of energy consumption at plants as well as in transportation. BioInvent focuses on handling environmental impact in all parts of the Company's operations and introduces improvement initiatives on an ongoing basis.

The Company also has a permit to import and export cell lines in accordance with the European Parliament's regulation. BioInvent uses genetically modified micro-organisms (GMM) in its research and development work and has permits for the so-called contained use of such organisms according to the Swedish Work Environment Authority's directions.

Quality and regulatory approval

The Company has a permit under the EU rules on producing investigational pharmaceutical products for clinical trials according to Good Manufacturing Practice (GMP). This permit was issued by the Swedish Medical Products Agency which conducts regular inspections to verify that production maintains the approved level of quality. BioInvent is also involved in auditing activity to ensure the quality of raw materials and that contracted services maintain a high standard.

BioInvent's preclinical studies to evaluate the safety of products are carried out through contract research organizations (CROs) in accordance with Good Laboratory Practice (GLP). Clinical trials are conducted according to Good Clinical Practice (GCP). In cases where tests are carried out on animals, they are conducted in laboratories that strictly adhere to the applicable regulations.

BioInvent has many years' experience of quality work, and endeavors to constantly improve the quality of all of its work.

Revenues and result

Net revenues amounted to SEK 82.9 million (80.7). Revenues for the period are derived from milestone payments from strategic partners and revenues from partners using the n-CoDeR® antibody library.

The Company's total costs amounted to SEK 211.1 million (264.7). Operating costs are divided between external costs of SEK 113.8 million (167.3), personnel costs of SEK 88.0 million (86.2) and depreciation of SEK 9.4 million (11.1). Restructuring costs (personnel costs) in connection with changes in the manufacturing operation amounting to SEK 6.0 million were charged to the Company's second quarter 2010 results.

Research and development costs amounted to SEK 178.9 million (229.2). Depreciation according to plan reduced the operating result for the period by SEK 9.4 million (11.1), of which depreciation of intangible fixed assets amounts to SEK 4.0 million (5.4).

The loss amounted to SEK -128.4 million (-176.7). The net financial items amounted to SEK -0.6 million (2.8). Earnings per share amounted to SEK -2.12 (-3.17).

Financial position and cash flow

As of 31 December 2010, the Group's current investments together with cash and bank amounted to SEK 106.1 million (84.0). The cash flow from current operations and investment activities amounted to SEK -122.3 million (-128.4).

In February 2010 BioInvent implemented a directed new share issue totalling 5,434,800 shares that raised SEK 150 million for the Company before transactions costs. The subscription price was set at SEK 27.60 per share.

The shareholders' equity amounted to SEK 74.2 million (55.6) at the end of the period. The Company's share capital was SEK 30.5 million. The equity/assets ratio at the end of the period was 53.7 (44.1) percent. Shareholders' equity per share amounted to SEK 1.21 (1.00). The Group had no interest-bearing liabilities.

The five-year review is described on page 58.

Investments

Investments in tangible fixed assets amounted to SEK4.6 million (1.3). No investments were made in intangible assets during the period (-).

Parent company

The BioInvent Group consists of the parent company, BioInvent International AB, and the subsidiary BioInvent Finans AB, which administers warrants issued by BioInvent International AB. Net revenues amounted to SEK 82.9 million (80.7). The loss amounted to SEK -125.8 million (-175.5). The cash flow from current operations and investment activities amounted to SEK -122.4 million (-128.2). The Parent company coincides in every material way with the Group.

The share

The BioInvent share has been listed on NASDAQ OMX Stockholm since 2001. As of 31 December 2010, share capital amounted to SEK 30.5 million, made up of 61,095,689 shares. Assuming that all options 1,920,090 issued due to the 2008/2012 employee stock option plan are exercised, the number of shares will be 63,015,779.

There is only one class of stock. Each share carries one vote at the Annual General Meeting and all shares carry equal right to a share in the assets and profits of the Company. The regulations in the Company's Articles of Association contain no restrictions on the transfer of shares. The Company is not aware of any agreements between shareholders that would restrict the right to transfer shares. Nor are there any agreements, in which the Company is a party, that may go into force, be amended or go out of force if control of the Company is changed as a result of a public purchase offer.

According to the Articles of Association, members of the Board of Directors are elected annually by the Annual General Meeting. The Articles of Association do not contain any restrictions regarding appointment or dismissal of Board members or changes in the Articles of Association.

The Annual General Meeting has not authorised the Board of Directors to take decisions on the issuance or acquisition of shares by the Company.

Corporate governance report

Based on the Annual Accounts Act, chapter 6, § 8, BioInvent has decided to produce a Corporate Governance Report that is separate from the Annual Report.

Future prospects

BioInvent's future revenue flows are primarily expected to come from co-operation agreements linked to own drug projects in the form of license fees, milestone payments and royalties on the final sale of its products, as well as from its own sales. Future revenue trends will largely depend on the success of outlicensing of the Company's product candidates and the results of future product development and launches.

Sustainable profitability is expected when one of our projects reaches the market. In the meantime, profit may be reported for individual years before this time, when essential breakthroughs are made in any of our projects.

Risks and risk management

Risks associated with pharmaceutical development

Developing a new biotech drug up to and including its launch costs about USD 1.3 billion (source: Tufts Center for the Study of Drug Development, January 2011). At the same time, statistically only one in ten drug candidates in clinical Phase I reaches the market, while the probability of successfully launching an antibody-based drug is somewhat higher. The likelihood of reaching the market increases as the project is moved forward in the development chain. However, the costs also increase, rising sharply in the late clinical phases. To sum up, the risk associated with developing a new drug is very high.

As the Company matures and the project portfolio develops, the Company's knowledge and experience in important areas continues to grow, which benefits all important decisions in the projects and collectively reduces the risk of investing in the wrong project.

Building a large project portfolio will, in the long term, make the Company less dependent on the success of individual projects. At this point, however, the portfolio is relatively limited and consists of projects in early phases – which means that a setback in an individual project may have a significantly negative impact on the Company.

Clinical trials and product responsibility

BioInvent endeavours to advance its projects through the value chain, which will mean increased expenses for clinical trials. Before any product under development can be sold, the Company or its partners must demonstrate the safety and efficacy of each potential product for human use, for each stated indication.

There is no guarantee that clinical trials carried out by the Company or its partners can demonstrate sufficient safety and efficacy to obtain necessary government authority approvals or that the trials will lead to competitive products. If during development the Company or its partners cannot demonstrate with sufficient reliability that the intended products are safe and effective, authorization for these products could be denied, which would mean that they cannot be launched on the market.

The use of the Company's products in clinical trials could lead to claims for damages being lodged against the Company in the event that such products cause illness, physical injury, death or damage to, loss of or destruction of property. BioInvent's activities are exposed to potential liability risks, which are a normal aspect of research, development and manufacture of biopharmaceutical products. The Company has a commercial insurance policy that provides coverage in the geographic markets in which BioInvent currently is active. Although the Company considers its insurance coverage to be adequate, the scope and amount of the policy are limited and there is no guarantee that coverage will be adequate in the event of a legal claim.

Cooperation agreements

Forming alliances with partners for several of the Company's clinical projects provides BioInvent with expertise and experience, while reducing the Company's own investment needs in the individual projects. This strategy also reduces BioInvent's risk level because the Company is able to invest in several projects.

Even if the Company tries to develop and strengthen such partnerships there is no guarantee that the collaboration will result in a successful product launch. There is always the risk that the partner could change its focus and priorities, which in turn could have a negative effect on the collaboration.

Competition and fast technological development

The market for all of the Company's future products is characterized by significant competition and fast technological development. BioInvent's competitors consist, among others, of major international pharmaceutical and biotech companies. Many of the competitors have far greater resources than BioInvent. There is always a risk that the Company's product concept will be subject to competition from a similar product or that entirely new product concepts will prove superior.

By allying itself with external research groups in the forefront of medical development, the Company hopes to gain access to target proteins that can be developed for long-term competitive medical treatment options. In order to further strengthen the Company's own position, great emphasis is placed on strong patent protection.

The selection of future partners will also be a crucial factor in the competitiveness of the Company's own products. BioInvent will therefore look for partnerships with companies that have an established and strong infrastructure, strategic commitment to future product development, and can provide the necessary resources.

Biotechnology and patent risk

The patents relate both to the Company's core technology for antibody drug development and various aspects thereof, as well as different antibody products under development and their use as drugs. There is no guarantee that the Company's products and processes which may in fact be covered by granted patents will not be attacked or contested by competitors or that granted patents will not infringe upon competitors' rights. BioInvent monitors and evaluates the activities, patents and patent applications of competitors on an ongoing basis for the purpose of identifying activities that are covered by the Company's intellectual property and patents that could cover parts of the Company's sphere of activity.

It may also be necessary to initiate legal proceedings to defend the Company's current or future patents, or to determine the extent and validity of patents that belong to a third party.

Changes in healthcare systems
In several countries proposals have been submitted to change the healthcare system in ways that could affect BioInvent's ability to profitably engage in its business.

BioInvent's success depends in part on the extent to which the Company's products qualify for various types of subsidies. Certain countries require that products must first undergo a lengthy review before public subsidies may be considered. Many of the countries in which the Company's future products could be commercialized have measures to curb rising healthcare costs. Such measures may be expected to continue and could result in stricter rules for both reimbursement levels and the medications covered.

Qualified personnel and key individuals
BioInvent is highly dependent on the Company's senior executives and other key individuals. Losing any of these key employees could delay or disrupt research programmes or development, outlicensing or commercialisation of the Company's product candidates. The Company's ability to attract and retain qualified personnel is crucial for its future successes. Even if BioInvent believes that the Company will be able to both attract and retain qualified personnel, it cannot guarantee that this will be able to occur on satisfactory terms in relation to the competition from other pharmaceutical and biotech companies, universities and other institutions.

Obtaining additional financial resources
The focus on producing drug candidates is expected to involve significant costs and generate annual revenue from products on the market in the longer term. Accordingly, the business is expected to continue to report a negative cash flow. The capital requirement is financed through (i) sales of rights to individual projects, (ii) partnerships that guarantee product financing, (iii) shareholders' equity. Failure to secure such financing could negatively affect the Company's business, financial position and operating income.

Principles of remuneration to Directors, the CEO and other senior executives
Remuneration of Directors, the CEO and other senior executives and auditors is described in notes 2 and 3.

The 2010 Annual General Meeting adopted principles of remuneration to the CEO and benefits for other senior executives. There were no deviations from these guidelines. The Board proposes that the principles of remuneration to the CEO and other senior executives remain unchanged and apply from the 2011 Annual General Meeting.

These guidelines will apply to those persons who during the period that the guidelines are in effect, belong to executive management and to other department heads who are directly subordinate to the CEO, referred to below as "senior executives".

BioInvent will offer compensation and terms of employment deemed necessary to recruit and retain qualified executives who are capable of achieving established goals. The overarching principle is to offer market-based salaries and other remuneration to senior executives at BioInvent. Senior executives will receive a fixed salary. In addition, variable compensation may also be paid to reward clearly target-related accomplishments in a simple and transparent way. Senior management's variable compensation will depend on the extent to which previously established targets are met within the frame of the Company's operation, mainly technical and commercial milestones within proprietary drug projects. Such targets will not be related to developments of the Company's share. Senior management's variable compensation will not exceed 30 percent of the fixed salary. Such remuneration can be pensionable.

The maximum result of variable compensation shall not entail costs for the Company in excess of a total of SEK 2.5 million (excluding social security costs), calculated based on the number of persons currently included in executive management (such costs may change proportionately if the number of persons in management should change).

Each year the Board of Directors will consider whether or not to propose a share-based incentive scheme to the Annual General Meeting. Issuance and transfer of ownership of securities resolved by the Annual General Meeting in accordance with the rules of chapter 16 of the Swedish Companies Act or the old "Leo" Act, are not covered by these guidelines to the extent that the Annual General Meeting has taken or will take such decisions.

Executive management's non-monetary benefits, such as company cars, computers, mobile phones, extra health insurance, or occupational health care, may be provided to the extent that such benefits are deemed market-based for senior executives in equivalent positions in the market where the Company is active. The collective value of these benefits must comprise a smaller portion of total compensation.

Senior executives have the right to retire with pension at the earliest from the date the individual reaches the age of 65. Senior executives will be covered by the prevailing ITP plan or a defined contribution occupational pension that does not exceed 35% of pensionable salary. Senior executives who reside outside Sweden or are foreign nationals and have their main pension in a country other than Sweden, may be offered other pension solutions that are reasonable in the relevant country. Such solutions must be defined contribution plans.

The total of dismissal and severance pay for members of senior management will not exceed 24 monthly salaries for the CEO and 12 monthly salaries for others senior executives.

According to Swedish law, the Annual General Meeting resolves on remuneration to board members and deputy board members to the extent such remuneration is for board-related duties. If a board member is employed by the Company, remuneration is paid to such board members in accordance with these guidelines. Board members who are employed by the Company will not receive separate compensation for board duties in the Company or Group companies. If a board member carries out duties for the Company that are not board duties, compensation will be paid that is market-based and with consideration taken to the nature and performance of the assignment. The Board's Remuneration Committee prepares and formulates proposals for the Board to resolve with respect to remuneration for the CEO.

The Board of Directors Remuneration Committee prepares, in consultation with the CEO, and decides on questions involving remuneration to other senior executives. The Board decides on issues relating to remuneration for board members for duties not included in the duties of the board, provided that this can be accomplished with the necessary majority, otherwise the Annual General Meeting decides on such matters.

The Board of Directors will have the right to depart from these guidelines if justified by particular circumstances in individual cases, provided that this is subsequently reported and explained.

At the time of the 2011 Annual General Meeting BioInvent does not have any remuneration undertakings due for payment.

Events after the end of the financial year
No significant events have occurred since the end of the financial year.

Proposed appropriation of profit
At the disposal of the Annual General Meeting: Share premium reserve of SEK 141,660,165 and loss for the year of SEK -125,844,676. The funds at AGMs disposal are thus SEK 15,815,489.

The Board proposes that the profit at the disposal of the Annual General Meeting of SEK 15,815,489 be carried forward. No dividend is proposed.

Consolidated statement of comprehensive income for the Group

Consolidated income statement for the Parent Company

		Group		Parent company	
SEK thousand	**Note**	**2010**	**2009**	**2010**	**2009**
Net revenues		82,866	80,659	82,866	80,659
Operating costs					
Research and development costs		-178,890	-229,187	-176,739	-228,207
Sales and administrative costs		-32,227	-35,466	-31,823	-35,239
Other operating revenues		986	5,896	986	5,896
Other operating costs		-575	-1,404	-575	-1,404
		-210,706	-260,161	-208,151	-258,954
Operating profit/loss	1-7	**-127,840**	**-179,502**	**-125,285**	**-178,295**
Profit/loss from financial investments					
Interest income and similar items	8	989	3,004	989	3,004
Interest costs and similar items	9	-1,549	-163	-1,549	-163
Profit/loss after financial items		**-128,400**	**-176,661**	**-125,845**	**-175,454**
Tax on profit for the year	10	-	-	-	-
Profit/loss for the year		**-128,400**	**-176,661**	**-125,845***	**-175,454***
Other comprehensive income					
Changes in actual value current investments		25	-211		
Comprehensive income		**-128,375**	**-176,872**		
Profit/loss pertaining to the Parent company's shareholders		-128,375	-176,872		
Earnings per share, SEK	11				
Before dilution		-2.12	-3.17		
After dilution		-2.12	-3.17		

*The Parent company's profit the year corresponds to the Parent company's comprehensive income.

Consolidated statement of financial position for the Group

Consolidated balance sheet for the Parent Company

		Group		Parent company	
SEK thousand	**Note**	**2010**	**2009**	**2010**	**2009**
ASSETS					
Fixed assets					
Intangible fixed assets					
Acquired intangible fixed assets	12	3,052	7,022	3,052	7,022
Tangible fixed assets					
Equipment	13	10,445	11,682	10,445	11,682
Investments in rented premises	13	750	287	750	287
		11,195	11,969	11,195	11,969
Financial fixed assets					
Shares in subsidiaries	14	-	-	100	100
Current assets					
Inventories					
Raw materials and consumables		683	1,553	683	1,553
Current receivables					
Accounts receivables	17	4,377	3,441	4,384	3,441
Other receivables	17	7,739	11,863	7,732	11,863
Prepaid expenses and accrued income	15	4,914	6,378	4,914	6,378
		17,030	21,682	17,030	21,682
Current investments and cash and bank*					
Current investments	17	69,118	9,984	69,109	9,986
Current investments that constitute liquid funds	17	14,964	45,974	14,963	45,987
Cash and bank	17	21,988	28,062	21,988	28,062
		106,070	84,020	106,060	84,035
Total assets		**138,030**	**126,246**	**138,120**	**126,361**

*See also specification at the bottom of page 36.

SEK thousand	Note	Group 2010	Group 2009	Parent company 2010	Parent company 2009
SHAREHOLDERS' EQUITY AND LIABILITIES					
Shareholders' equity				Restricted Equity	
Share capital		30,548	27,830	30,548	27,830
Other allocated capital		946,820	805,160		
Statutory reserve				27,831	203,285
Reserves		11	-14		
				58,379	231,115
				Non-restricted Equity	
Share premium reserve				141,660	-
Accumulated loss		-903,188	-777,343		
Profit/loss for the year				-125,845	-175,454
				15,815	-175,454
Total shareholders' equity		**74,191**	**55,633**	**74,194**	**55,661**
Shareholder's equity pertaining to the Parent company's shareholders		74,191	55,633		
Current liabilities					
Accounts payables	17	17,282	16,510	17,282	16,510
Liabilities to subsidiaries				101	101
Other liabilities	17	26,305	34,467	26,306	34,468
Accrued expenses and deferred income	16, 17	20,252	19,636	20,237	19,621
		63,839	70,613	63,926	70,700
Total shareholders' equity and liabilities		**138,030**	**126,246**	**138,120**	**126,361**
Pledged assets		-	-	-	-
Contingent liabilities		-	-	-	-

Consolidated statement of cash flows for the Group

Consolidated statement of cash flows for the Parent Company

	Group		Parent company	
SEK thousand	**2010**	**2009**	**2010**	**2009**
Current operations				
Operating profit/loss	-127,840	-179,502	-125,285	-178,295
Adjustments for other non-cash items				
Depreciation	9,372	11,117	9,372	11,117
Other adjustments for non-cash items	2,555	1,207	-	-
Interest received	660	4,886	660	4,886
Interest paid	-2	-163	-2	-163
Cash flow from current operations before changes in working capital	**-115,255**	**-162,455**	**-115,255**	**-162,455**
Changes in working capital				
Changes in inventories	870	267	870	267
Changes in current receivables	3,459	28,561	3,434	28,772
Changes in current liabilities	-6,774	6,484	-6,774	6,484
	-2,445	**35,312**	**-2,470**	**35,523**
Cash flow from current operations	**-117,700**	**-127,143**	**-117,725**	**-126,932**
Investment activities				
Acquisition of tangible fixed assets	-4,628	-1,297	-4,628	-1,297
Cash flow from investment activities	**-4,628**	**-1,297**	**-4,628**	**-1,297**
Cash flow from current operations and investment activities	**-122,328**	**-128,440**	**-122,353**	**-128,229**
Financing activities				
Directed new share issue	144,378	-	144,378	-
Cash flow from financing activities	**144,378**	**-**	**144,378**	**-**
Changes in current investments**	**-59,134**	**151,196**	**-59,123**	**151,033**
Change in liquid funds	**-37,084**	**22,756**	**-37,098**	**22,804**
Opening liquid funds	74,036	51,280	74,049	51,245
Liquid funds at year-end	**36,952**	**74,036**	**36,951**	**74,049**
Liquid funds, specification:				
Current investments that constitute liquid funds*	14,964	45,974	14,963	45,987
Cash and bank	21,988	28,062	21,988	28,062
	36,952	**74,036**	**36,951**	**74,049**
Current investments**	69,118	9,984	69,109	9,986
	106,070	**84,020**	**106,060**	**84,035**

*duration less than 3 months

**duration more than 3 months

Statement of changes in equity for the Group

Statement of changes in equity for the Parent Company

GROUP

SEK thousand	Share-capital	Other allocated capital	Reserves	Accumulated loss	Total
Shareholders' equity 31 December 2008	**27,830**	**805,160**	**197**	**-601,889**	**231,298**
Profit/loss for the year				-176,661	-176,661
Changes in actual value current investments			-211		-211
Total, excluding transactions with equity holders of the Company	**27,830**	**805,160**	**-14**	**-778,550**	**54,426**
Effect of employee incentive programme				1,207	1,207
Shareholders' equity 31 December 2009	**27,830**	**805,160**	**-14**	**-777,343**	**55,633**
Profit/loss for the year				-128,400	-128,400
Changes in actual value current investments			25		25
Total, excluding transactions with equity holders of the Company	**27,830**	**805,160**	**11**	**-905,743**	**72,742**
Effect of employee incentive programme				2,555	2,555
Directed new share issue	2,718	141,660			144,378
Shareholders' equity 31 December 2010	**30,548**	**946,820**	**11**	**-903,188**	**74,191**

Shareholders' equity is attributable in its entirety to shareholders of the Parent company. The share capital as of 31 December 2010 consists of 61,095,689 shares and the share's ratio value is 0.5. The directed new share issue carried out in February 2010 raised SEK 144,378 thousand after issue expenses, which amounted to SEK 5,622 thousand.

PARENT COMPANY

SEK thousand	Share-capital	Statutory reserve	Share premium reserve	Non-restricted equity	Total
Shareholders' equity 31 December 2008	**27,830**	**186,418**	**0**	**16,867**	**231,115**
Appropriation of profit/loss		16,867		-16,867	0
Profit/loss for the year*				-175,454	-175,454
Shareholders' equity 31 December 2009	**27,830**	**203,285**	**0**	**-175,454**	**55,661**
Appropriation of profit/loss		-175,454		175,454	0
Profit/loss for the year*				-125,845	-125,845
Directed new share issue	2,718		141,660		144,378
Shareholders' equity 31 December 2009	**30,548**	**27,831**	**141,660**	**-125,845**	**74,194**

*The Parent company's profit for the year corresponds to the Parent company's comprehensive income.

Accounting principles and information notes

Statement of compliance with the applicable rules
The consolidated accounts have been prepared in accordance with International Financial Reporting Standards (IFRS). Since the Parent Company is an enterprise within the EU, only EU-approved IFRS will be applied. Moreover, the consolidated accounts are prepared in compliance with the Annual Accounts Act through the application of the Swedish Financial Reporting Board's recommendation RFR 1.3, Supplementary Accounting Regulations for Groups. The Parent Company's annual accounts have been prepared in compliance with Annual Accounts Act and with application of the Swedish Financial Reporting Board's recommendation RFR 2.3, Reporting for Legal Entities.

Critical accounting issues and accounting estimates
Senior management and the Board of Directors make estimates and assumptions about the future. These estimates and assumptions affect reported assets and liabilities, as well as revenues and expenses and other disclosures. These assessments are based on historical experience and the various assumptions that are assessed to be reasonable under prevailing circumstances. Actual outcomes can differ from these assessments if other assumptions are made or other conditions arise.

Conditions of material importance for the report which were specifically reviewed during the year are revenues and expenses in collaboration agreements.

Accounting principles
The Group introduced the following new and amended IASB standards and IFRIC statements on 1 January 2010:

- IFRS 2 Share-Based Payment – Amendment. The Group's share-based payments settled in cash (Approved by the EU on 23 March 2010 and to be applied in financial years beginning on 1 January 2010 or later)
- IFRS 3R Business Combinations and IAS 27R Consolidated and Separate Financial Statements (Approved by the EU on 3 June 2009 and to be applied in financial years beginning on 1 July 2009 or later)
- IAS 39 Financial Instruments: Recognition and Measurement – Amendment. Items qualifying for hedge accounting (Approved by the EU on 15 September 2009 and to be applied in financial years beginning on 1 July 2009 or later)
- IFRIC 12 Service Concession Arrangements (Approved by the EU on 25 March 2009 and to be applied in financial years beginning on 1 April 2009 or later)
- IFRIC 15 Agreements for the Construction of Real Estate (Approved by the EU on 22 July 2009 and to be applied in financial years beginning on 1 January 2010 or later)
- IFRIC 16 Hedges of a Net Investment in a Foreign Operation (Approved by the EU on 4 June 2009 and to be applied in financial years beginning on 1 July 2009 or later)
- IFRIC 17 Distributions of Non-Cash Assets to Owners (Approved by the EU on 26 November 2009 and to be applied in financial years beginning on 1 November 2009 or later)
- IFRIC 18 Transfers of Assets from Customers (Approved by the EU on 27 November 2009 and to be applied from financial years beginning on 1 November 2009 or later)

The application of these standards and interpretations has not had any effect on the Group's financial results or position.

Below is a list of the new standards and interpretations that will be applied for the 2011 calendar year or later. The future application of the standards and interpretations below are not, unless specifically indicated, expected to have any effect on the Group's financial results or position.

- IFRS 9, Financial Instruments: Recognition and Measurement (Not yet approved by the EU and there is no schedule for approval at this time)
- IAS 24 Related Party Disclosures – Amendment (Approved by the EU on 19 July 2010)
- IAS 32, Financial Instruments: Classification – Amendment. Classification of rights issues (Approved by the EU on 23 December 2009)
- IFRIC 14 Prepayments of a Minimum Funding Requirement– Amendment (Approved by the EU on 19 July 2010)
- IFRIC 19 Extinguishing Financial Liabilities with Equity Instruments (Approved by the EU on 23 July 2010)
- IFRS 7 Financial Instruments: Disclosures – Amendment (Expected to be approved by the EU in Q2 2011)

Basis for preparation of the accounts
The consolidated accounts are based on historical acquisition values, with the exception of financial assets intended for trading and financial derivatives, which are carried at fair value.

The BioInvent Group consists of the Parent Company, BioInvent International AB, and the wholly owned subsidiary BioInvent Finans AB, which administers the warrants issued by BioInvent International AB. The consolidated financial statements are prepared using the acquisition method. Accordingly, shareholders' equity in the subsidiaries is entirely eliminated upon acquisition. The Group's equity consists of the equity in the Parent Company and the equity in the subsidiaries accrued after the acquisition.

Segment reporting
BioInvent's executive officers, Board and management team monitor and manage the Company's operations based on the financial results and position at the consolidated level without dividing the business into segments. BioInvent develops antibodybased drugs. The Company's risks and opportunities are mainly affected by the progress of the projects. The Company engages in integrated activities, in which the projects are considered to carry similar risks and opportunities, and there is therefore only one business segment, which is apparent in the consolidated income statement, balance sheet, cash flow statement and the notes associated with these.

The Company's revenues originate from different geographic areas; however, the Company's risks and opportunities in these geographic areas are similar. All sales take place through the Company's own sales organisation in Sweden.

Net revenues, fixed assets and investment activities	2010	2009
Net revenues		
Sweden	0.1	-
Europe	60.9	61.6
Other countries	21.9	19.1
	82.9*	80.7**
Fixed assets		
Sweden	**14.2**	**19.0**
Investment activities		
Sweden	**4.6**	**1.3**

* The revenues come mainly from six customers and include BioInvent's portion, SEK 38.3 million, of milestone payment when Roche in May 2010 started a new clinical study of TB-403.

** The revenues come mainly from six customers and include BioInvent's portion, SEK 21.7 million, of the first milestone payment from Roche for TB-403.

Revenue recognition
BioInvent's net revenues consist of:

- revenues from collaboration agreements associated with outlicensing of proprietary projects
- revenues from technology licenses and
- revenues from external development projects.

Revenue is reported at the actual value of what has been received or will be received. Revenues are recognised to the extent that it is likely that financial benefits will arise for the Company, and revenues can be calculated reliably.

Revenue from *collaboration agreements associated with outlicensing* of proprietary projects consist of initial license fees, milestone payments and remuneration for development work as well as future royalties on sales of the medication. Initial license fees (upfront payments) are received at the time of signing of the agreement. These payments are recognised as revenue in their entirety when the collaboration agreement is signed provided that BioInvent have met all obligations in accordance with the agreement. Milestone payments are received when the outlicensed drug project passes essential steps in the development process, such as the start of different clinical phases. Milestone payments are recognised when all terms and conditions of the agreement are met. Payment for development work in conjunction with collaboration agreements is recognised as the work is completed.

Revenues from technology licenses refers to access fees for a technology, maintenance fees for the license, milestone payments and future royalties on the sale of products developed under the license. Access fees for technology are recognised as revenue when all obligations of the agreement are met. Maintenance fees are treated on an accrual basis over the period of the license.

BioInvent also carries out *external development projects* such as developing antibody candidates and process development. In such agreements BioInvent receives ongoing compensation for work carried out and in connection with agreements for developing antibody candidates from the n-CoDeR antibody library also milestone payments as well as future royalties on product sales. Ongoing compensation for work carried out is recognised as revenue as the project is completed in accordance with the principle for the percentage of completion method. Revenues and expenses as well as profit and loss are reported in the accounting period during which the work is carried out. If a risk of loss is deemed to exist, individual provisions are performed on an ongoing basis.

Government grants are recognized as revenue at actual value when it is reasonable to assume that the subsidy will be received and that all associated conditions will be met. When the subsidy is linked to a cost, it is reported as income during the periods required to offset the cost reported in a systematic way and for which the subsidy is intended to compensate. Government grants are reported in the income item other operating revenue.

Interest income is recognised in the period to which it relates based on the effective interest method. Effective interest is the interest that results in the present value of all future payments during the fixed interest term being equivalent to the carrying amount of the asset. Interest income is reported as financial income, see note 7.

Research and development costs
Research costs are expensed as they occur. Costs for development of new products are not capitalized, unless the criteria in IAS 38 have been met. Since the Company's drug projects are quite a long time away from being registered as products that can be sold and thereby generate a financial gain for the Company, no costs for development of products are capitalized, i.e. no intangible assets developed by BioInvent have been capitalized.

Remuneration to employees
Short-term remuneration
The Company reports short-term remuneration to employees as a cost during the period that the employee carries out the work for which he/she is being compensated.

Compensation after end of employment
BioInvent mainly has defined benefit pension obligations. BioInvent's pension commitment is secured by an Alecta insurance policy. According to a statement issued by the Swedish Financial Reporting Board, UFR 3, this is a benefit-based plan that covers several employers. For the 2010 financial year, the Company did not have access to the information necessary to report this plan as a benefit-based plan. The ITP pension plan secured by an Alecta insurance is therefore reported as a premium based plan. At the end of 2010 Alecta's surplus in the form of the collective funding ratio was 146 percent (141). The collective consolidation level consists of the market value of Alecta's assets expressed as a percentage of insurance commitments calculated according to Alecta's actuarial assumptions. Note 2 provide information about the premiums for Alecta pension insurance. The Company reports pension payments as a cost during the period that the employee carries out the work to which the benefit relates.

Compensation in connection with notice of termination
Compensation in connection with termination of employment is reported as a cost where the Company is obliged to prematurely terminate an employee's employment.

Share-related compensation
The Annual General Meeting on 14 April 2008 resolved to adopt the employee stock option programme 2008/2012. The Annual General Meeting on 21 April 2009 decided on a supplement to the programme. This programme is described in greater detail in note 2.

Disclosure of related party transactions
There are no transactions with related parties, in accordance with IAS 24, to report.

Leasing
The Group's leasing agreements have been categorized as operational leases. Leasing charges are expensed in the income statement over the period of the lease based on usage.

Taxes
Deferred tax shall be reported in the balance sheet, which means that deferred tax is calculated for all identified temporary differences between, on the one hand, the fiscal value of assets and liabilities, and on the other hand, their reported value. There are no substantial deferred taxes that relate to temporary differences as of 31 December 2010.

Deferred tax assets relating to unutilised loss carry-forwards and deductible temporary differences are only reported if it is likely that they will be utilised against future taxable earnings. The Group's accumulated unutilised loss carry-forwards amounted to SEK 937 million as of 31 December 2010. It is unclear when these loss carry-forwards will be utilised for deduction against taxable earnings. Deferred income tax recoverable relating to loss carry-forward is therefore not reported at any value.

Intangible fixed assets
Externally acquired technology licenses that can be used broadly in the operation have been capitalized. These technology licenses supplement the proprietary technology platform where they are expected to offer competitive advantages. Cash payment for the acquisitions is capitalized taking into account the fact that a market value exists since the price was arrived at through negotiation between two independent parties. Intangible assets have a finite useful life and are stated at cost less accumulated amortisation and impairment losses, if any. Such intangible assets are amortised over their estimated useful lives. The useful life assigned to an asset is evaluated on an ongoing basis and changed if necessary. However, the Company is conservative in its estimate of the usage period of acquired intangible assets, taking into account the constant, rapid development within the biotech industry. Such assets are therefore amortised over a period of up to 5 years.

Tangible fixed assets
Tangible fixed assets are valued at the acquisition value less accumulated depreciation. Tangible fixed assets are depreciated or amortised according to the straight-line method over the expected useful life of the assets. The useful life assigned to an asset is evaluated on an ongoing basis and changed if necessary.

Depreciation/amortisation according to plan is as follows:	
Equipment	5 years
Investments in rented premises	5–10 years

Inventories
Inventories are valued according to the lowest value principle and the first in, first out (FIFO) method. This means that the inventories are reported at the lowest of the acquisition value according to the FIFO method and the actual value.

Impairment
The carrying amounts of the Group's assets are checked on each balance sheet date to determine whether there is any indication that an impairment loss is necessary.

Impairment test of tangible and intangible assets and shares in subsidiaries, etc.
If there is any indication of impairment, the asset's recoverable value is calculated according to IAS 36 (see below). The estimated recoverable amount is assessed annually for intangible assets with an indefinite useful life and intangible assets that are not yet ready for use. If it is not possible to establish material independent cash flows for an individual asset, when assessing these assets the impairment requirement will be grouped at the lowest level at which it is possible to identify material independent cash flows (a so-called cash generating unit). Taking into account the specific nature of the business, BioInvent regards the entire business as one cash generating unit. A significant portion of the reported assets is used to generate the Company's total cash flow. Accordingly, if an asset cannot be assessed separately, it will be assessed with all assets included in the cash-generating unit.

Impairment is indicated when the reported value of an asset or cash-generating unit (group of units) exceeds the recovery value. An impairment loss is recognised in the income statement.

The recoverable amount is the higher of fair value less selling expenses and value in use. When calculating value in use, the future cash flow is discounted by a discounting factor which takes into consideration risk-free interest and the risk associated with the specific asset.

Impairment testing for financial assets
On each reporting date, the Company evaluates whether there is objective evidence that a financial asset or pool of assets is impaired. Objective evidence comprises observable conditions that occurred and that have a negative impact on the possibility of recovering the cost of the asset.

The recoverable amount of assets in the category loan receivables and accounts receivable, which are recognised at amortised cost, is determined as the present value of future cash flows discounted at the effective rate at initial recognition of the asset. Assets with short maturities are not discounted. An impairment loss is recognised in the income statement.

Reversal of impairment losses
An impairment loss is reversed if there is an indication that the need for impairment no longer exists and there has been a change in the estimates used to determine the asset's recoverable amount. An impairment loss is only reversed if the asset's reported value after reversal does not exceed the reported value that the asset would have had if the impairment loss had not been made.

Impairment losses of loan receivables and accounts receivable that are reported at amortised cost are reversed if a later increase in the recoverable amount can objectively be attributed to an event that occurred after the impairment loss was made.

Transactions in foreign currencies
The consolidated financial statements are presented in Swedish kronor, which is the Company's functional and reporting currency. Transactions in foreign currencies are translated when they are entered in the accounts into the reporting currency, according to the spot rate on the transaction day. Receivables and liabilities in foreign currencies have been translated at the closing day exchange rate. Exchange rate gains and losses on operating receivables and liabilities are charged to the operating profit/loss. Gains and losses on financial receivables and liabilities are reported as financial items.

Financial Instruments
A financial instrument is any contract that gives rise to a financial asset, financial liability, or equity instrument in another company. For BioInvent this encompasses liquid funds, current investments, accounts receivables, other receivables, accounts payables, other liabilities, accrued expenses and derivative instruments. Liquid funds consist of cash and bank balances, as well as short term investments with maturity shorter than 3 months. Current investments consist of investments with maturity longer than 3 months, but no longer than 12 months.

Recognition of financial instruments
A financial asset or a financial liability is reported in the balance sheet when the Company becomes a party to the instrument's contractual terms and conditions. Accounts receivable are recognised in the balance sheet when an invoice is sent. A liability is recognised when the counterparty has performed under the agreement and there is a contractual obligation to settle, even if no invoice has been received. Accounts payable are recognised when an invoice has been received. A financial asset is derecognised from the balance sheet when the rights in the agreement are fulfilled, due, or the Company loses control of them. The same applies to part of a financial asset. A financial liability is derecognised in the balance sheet when the obligations of the contract have been met or otherwise concluded. The same applies to part of a financial liability. Acquisitions and disposals of financial assets are recognised on the date of the transaction, which is the date on which the Group undertakes to acquire or divest the asset.

Classification and measurement of financial instruments
The classification depends on the acquirer's intention with the acquisition of the financial instrument. Financial assets and liabilities are classified in the following categories.

Financial assets and financial liabilities carried at fair value through profit or loss for the year
This category consist of two sub-categories: financial assets held for trading and other financial assets that the Company initially decided to classify in this category. A financial asset is classified as held for trading if it is acquired for the purpose of selling in the near term. Example of assets classified in this category is derivatives with positive values. Assets in this category are measured on an ongoing basis at fair value and changes in value are recognised through profit or loss for the year.

Held-to-maturity investments
This category includes non-derivative financial assets with fixed or determinable payments and with specified terms, which a company intends and has the ability to hold until maturity. These investments are valued at amortised cost.

Loan receivables and accounts receivables
Loan receivables and accounts receivables are financial assets that are not derivatives with fixed payments or with determinable payments that are not quoted on an active market. Assets in this category are valued at amortised cost. The amortised cost is determined based on the effective interest calculated at the time of acquisition. Assets with short maturities are not discounted. Accounts receivable are reported at the amount expected to be received and are individually assessed. Impairment losses on accounts receivables are recognised in operating expenses. Other receivables with an expected maturity of more than one year are classed as noncurrent. Those with shorter maturities are classed as other receivables.

Available-for-sale financial assets
Available-for-sale financial assets are non-derivatives that are either designated in this category or not classified in any of the three aforementioned categories. An example of assets that are classified in this category is interest-bearing securities. Assets in this category are continuously valued at fair value and are included in other comprehensive income.

Financial liabilities recognised at fair value through profit or loss for the year
This category consists of financial liabilities held for trading, such as derivatives with negative values. Liabilities in this category are continuously valued at fair value with changes in value recognised through profit or loss for the year.

Other financial liabilities
This category includes loans and other financial liabilities, such as accounts payables. Liabilities are valued at amortised cost. Accounts payable have a short expected maturity and are valued without discounting at a nominal amount. Noncurrent liabilities have an expected maturity longer than one year, while current liabilities have a maturity shorter than one year.

Hedge accounting
In order to apply hedge accounting the following criteria must be met: the position being hedged is identified and exposed to exchange-rate or interest-rate movements, the purpose of the instrument is to serve as a hedge and that the hedging effectively protects the underlying position against changes in the market rates. Financial instruments used for the purpose of hedging future currency flows are accounted for as hedges if the currency flows are considered probable to occur. BioInvent has chosen not to apply hedge accounting because the criteria cannot always be deemed to be met. Changes in fair value of such derivative instruments are therefore recognised in the income statement.

Financial risks
Currency risks
Bioinvent's currency exposure has increased as the development projects move forward in the value chain. Costs of services such as toxicological studies and clinical trials have increased. These services are often carried out abroad and are paid for in foreign currencies. At the same time the percentage of revenues in foreign currencies has increased.

Currency flows in conjunction with the purchase and sale of goods and services in currencies other than SEK generate transaction exposure. Currency exposure is primarily eliminated by matching flows in the same currency. When matching of underlying receivables and liabilities is not possible, the currency exposure is eliminated through forward contracts.

In 2010 95 percent (67) of revenues were invoiced in foreign currencies, mainly EUR. Around 36 percent (48) of costs in 2010 were invoiced in foreign currencies, mainly in USD, EUR and GBP. Realised forward contracts for flows in 2010 had an effect on the operating income in the amount of SEK 0.6 (-2.3) million. A sensitivity analysis shows that the Company's operating profit/loss in 2010 before hedging transactions would have been affected in the amount of SEK -0.3 million if the Swedish krona had weakened by 1 percent compared with USD and in the amount of SEK +0.4 million if the Swedish krona had weakened by 1 percent compared with EUR.

Interest risk
BioInvent's exposure to market risk for changes in interest levels is related to bank balances and corporate and bank certificates. To reduce the effect of the fluctuation in market interest rates, the excess liquidity is invested with different maturities so that the investments mature on a regular basis over the subsequent twelve-month period.

The average interest rate in 2010 was 0.7 percent (1.6). A change in the interest rate of 1 percent in 2010 would have affected the net interest income by SEK 1.4 million.

Liquidity and credit risk
Liquidity risk is minimized by liquidity planning and investment in financial instruments that can be redeemed at short notice. Only investments in interest bearing securities with low credit risk and high liquidity are permitted. There are also limitations in the amount that can be invested with an individual counterparty to avoid concentration of credit risk.

In accordance with the Company's financial policy excess liquidity is placed in bank accounts and invested in corporate and bank certificates with a K1 rating or equivalent. Corporate and bank certificates carry fixed interest rates and may have terms of up to one year.

BioInvent works with established and creditworthy counterparties. A credit assessment is carried out for all partners who will receive some form of credit. In addition, BioInvent monitors receivables on a constant basis. The Company's exposure to doubtful receivables is therefore low.

NOTE 1 Key ratios human resources

	2010	2009
Absence due to illness		
Total absence due to illness[1]	1.9%	2.3%
Of which long-term absence >60 days	0.7%	0.8%
Absence due to illness, women[2]	2.2%	2.4%
Absence due to illness, men[2]	1.5%	2.1%
29 years or younger[2]	0.9%	2.1%
30-49 years[2]	1.7%	1.8%
Older than 50 years[2]	2.6%	3.6%
Average number of employees, of which women	**96 (62%)**	**105 (63%)**
Age distribution		
-30 years	8%	8%
31-40 years	42%	45%
41-49 years	25%	20%
50- years	25%	27%
Staff turnover[3]	**3.1%**	**2.6%**

1) Absence is indicated as a percentage of total normal working hours.

2) Absence is indicated as a percentage of the group's total normal working hours.

3) Staff turnover is shown as the number of individuals leaving the Company as a percentage of the average number of employees. The reorganisation implemented in April 2010 is not included in the staff turnover figures for 2010.

NOTE 2 Salaries, other remuneration and social security

	2010		2009	
SEK thousands	Salaries and other remuneration	Social security costs (of which pension costs)	Salaries and other remuneration	Social security costs (of which pension costs)
Parent company	54,332	29,387 (9,613)	55,800	27,422 (8,417)
Subsidiaries	-	-	-	-
Group total	**54,332**	**29,387 (9,613)**	**55,800**	**27,422 (8,417)**

Salaries and other remuneration distributed between the Board of Directors, the CEO and other employees.

	2010		2009	
SEK thousands	Board and CEO	Other employees	Board and CEO	Other employees
Parent company	4,093	50,239	4,100	51,700
Subsidiaries	-	-	-	-
Group total	**4,093**	**50,239**	**4,100**	**51,700**

NOTE 2 Salaries, other remuneration and social security, continued

Pension costs distributed between the Board of Directors, the CEO and other employees.

	2010		2009	
SEK thousands	Board and CEO	Other employees	Board and CEO	Other employees
Parent company	852	8,761	927	7,490
Subsidiaries	-	-	-	-
Group total	**852**	**8,761**	**927**	**7,490**

BENEFITS FOR SENIOR EXECUTIVES

Principles

The Annual General Meeting resolves on remuneration for Board Members, including remuneration for committee work, based on the proposal from the Nominating Committee.

Benefits for CEO and other senior executives were determined in accordance with the 2010 Annual General Meeting. The Board determines the fixed salary of the CEO annually. The Board's Remuneration Committee determines the fixed salary of other senior executives annually. In addition to a fixed salary, variable remuneration may be payable according to the incentive scheme described below.

BioInvent's programme for variable remuneration for the CEO and other senior executives consists of a variable remuneration model that was introduced in 2003.

Variable performance-related remuneration of 0–30 percent of fixed annual cash salaries may be paid out on an annual basis to senior executives. The performance-related components in the current programme, for the period 1 January – 31 December 2011, are based primarily on high expectations for technical and commercial milestones in proprietary drug projects. The Board of Directors resolved in February 2010 to pay variable remuneration to the CEO, SEK 108 thousand, and other senior executives, SEK 283 thousand, for the period 1 January – 31 December 2010. Variable remuneration is pensionable income.

In addition, the CEO and other senior executives are covered by an employee stock option incentive programme, described on page 43.

Remuneration and other benefits in 2010

	Fixed salary	Board and committee fees	Variable remuneration	Other benefits	Pension costs	Total
Board and CEO						
Karl Olof Borg, Chairman		400				400
Carl Borrebaeck, member	618			60	130	808
Lars Backsell, member		180				180
Lars Ingelmark, member		200				200
Elisabeth Lindner, member		180				180
Björn Nilsson, member		210				210
Kenth Petersson, member		200				200
Svein Mathisen, CEO and member	1,937		108	0	722	2,767
	2,555	**1,370**	**108**	**60**	**852**	**4,945**
Other senior executives (5 individuals)	**5,820**	**-**	**283**	**257**	**1,778**	**8,138**
Total	**8,375**	**1,370**	**391**	**317**	**2,630**	**13,083**

Benefits for the Board and CEO

The Board's fees were set by the 2010 Annual General Meeting at SEK 400 thousand for the Chairman of the Board and SEK 160 thousand for each of the other members of the Board not employed by the Company. In addition hereto, but not to the Chairman of the Board, it was decided that SEK 50 thousand shall be the fee for the Chairman of the Audit Committee and SEK 40 thousand shall be the fee for each of the other members in the Audit Committee and SEK 20 thousand shall be the fee for each of the members in the Remuneration Committee.

Carl Borrebaeck, a member of BioInvent's Board, is the Company's Senior Scientific Advisor. In 2010 he received SEK 618 thousand in cash gross salary and SEK 60 thousand in other benefits (primarily car benefits). He received no Board fees in 2010. Carl Borrebaeck is entitled to pension benefits under the ITP plan. Retirement age is 65. The total cost of Carl Borrebaeck's pension benefits amounted to SEK 130 thousand in 2010. Carl Borrebaeck and the Company have a mutual period of notice of six months. He is not entitled to any redundancy pay over and above his salary during the period of notice.

The President and CEO, Svein Mathisen, received a fixed gross cash salary in 2010 of SEK 1,937 thousand and SEK 108 thousand in variable remuneration, as well as SEK 0 thousand in other benefits. The CEO has a defined contribution retirement benefit that may not exceed 35 percent of the wage calculation base. Retirement age is 65. The total cost of the CEO's pension benefits amounted in 2010 to SEK 722 thousand. The CEO and the Company have a mutual period of notice of six months. If notice is given by the Company, the CEO is entitled to redundancy pay equivalent to 18 monthly salaries. Redundancy pay is not deducted from other income. If the CEO resigns, no redundancy pay is payable. The CEO has received a basic allotment of 7,500 employee options in 2008 and an extra allotment of 7,500 employee options in February 2009, an extra allotment of 6,000 employee options in January 2010 and an extra allotment of 3,000 employee options in February 2011.

NOTE 2 Salaries, other remuneration and social security, continued

Benefits for other senior executives
Other senior executives are the individuals who, in addition to the CEO, are part of senior management. The retirement age for these senior executives is 65 and they are covered by the prevailing ITP plan or defined contribution occupational pension that does not exceed 35 percent of the wage calculation base. Employees residing outside Sweden, or who are foreign nationals and have their main pension in a country other than Sweden, may be offered other pension solutions that are reasonable in the relevant country, provided that the solution is a defined contribution pension plan. The Company and the other senior executives have a mutual period of notice of six months. Other senior executives are not entitled to redundancy pay over and above the payment of salaries during the period of notice.

Other senior executives received a fixed gross cash salary in 2010 of SEK 5,820 thousand and SEK 283 thousand in variable salary, as well as SEK 257 thousand in other benefits (primarily car benefit). The total pension costs relating to other senior executives in 2010 amounted to SEK 1,778 thousand. Other senior executives received a basic allotment of 105,000 employee options in 2008 and 2009 and also an extra allotment of 30,000 employee options in February 2009, an extra allotment of 30,000 employee options in January 2010 and an extra allotment of 15,000 employee options in February 2011.

Academic partnerships
An important aspect of BioInvent's strategy is to develop and maintain a research base with ties to a number of academic institutions. One such relationship, with the department of Immunotechnology at Lund University, is particularly strong. BioInvent provides research funding to the institution and in return BioInvent obtains the results and patent rights that arise from the partnership.

Carl Borrebaeck is a professor and responsible for these activities at the Department of Immunotechnology. Carl Borrebaeck has not participated in preparations or decisions relating to agreements that BioInvent has entered into with Lund University.

Percentage of women/men on the Board and in senior positions

	2010		2009	
	Number*	Of which women	Number*	Of which women
Board and CEO	9	22%	9	22%
Other senior executives	5	20%	5	20%

*Number on 31 December

Employee stock option plan 2008/2012
The Annual General Meeting on 14 April 2008 resolved to adopt an incentive programme, Employee Stock Option Plan 2008/2012, comprising a maximum of 1,450,000 employee options, and to issue 1,920,090 warrants for the subsidiary BioInvent Finans AB, free of charge, to secure the Company's commitment under the incentive programme and to cover the Company's associated social security contributions. BioInvent Finans AB subscribed to all warrants. Each option entitles the holder to subscribe to a new share at a subscription price of SEK 26.84. Employees received the basic allotment of 513,750 employee options in 2008 and 2009.

Employees received an extra allotment of 69,750 employee options in February 2009, an extra allotment of 429,750 employee options in January 2010 and an extra allotment of 37,875 employee options in February 2011. The annual general meeting on 21 April 2009 resolved to adopt an amendment to the existing employee options programme 2008/2012. The amendment programme comprise a maximum of 240,250 employee options. Each employee option entitles the holder to subscribe to a new share at a subscription price of SEK 26.84. A basic allocation of 33,750 employee options took place during 2009 and 2010. Extra allotment of 8,127 employee options took place in January 2010.

The employee options are free of charge and are not transferable. Exercise of the employee options requires that the option holder is still employed by the Group. Basic allotment complies with the following guidelines: (i) 7,500 options to the CEO, members of senior management, the heads of a section and persons with other key positions (about 15 people), except for members of senior management without a substantial shareholding in the Company, who will receive 30,000 options, and (ii) 3,750 options to other employees (about 90 people). Further, extra allotment may be obtained based on performance according to the following guidelines: (i) maximum 15,000 employee options each year 2009-2011 to the CEO and other members of management, (ii) maximum 7,500 employee options each year 2009-2011 to heads of sections and other key employees and (iii) maximum 3,750 employee options for 2010 to other employees. The maximum basic allotment may be adjusted proportionate to the length of employment with the Company for each individual. Extra allotment will be adjusted proportionate to the length of employment with the Company.

Basic allotment may take place until the 2010 Annual General Meeting. Employee stock options received through basic allotment within the framework of Employee Stock Option Programme 2008/2012 entitle the holder to exercise 50 percent of the options from the three-year anniversary of the allotment and 50 percent from the four-year anniversary of the allotment. Employee options received within the framework of the amendment programme can be exercised from 1 November 2012. The extra allotment is carried out in connection with the year-end report for 2008, 2009, and 2010 respectively. Employee stock options received through extra allotment within the framework of Employee Stock Option Programme 2008/2012 may be exercised from the 2012 Annual General Meeting and options received through extra allotment within the framework of the amendment programme may be exercised from 1 November 2012. 1 December, 2012, is the last day on which employee options may be exercised.

Assuming that all issued options relating to the Employee stock option plan 2008/2012, including the amendment programme, are exercised for subscription of new shares, the Company's share capital will increase by SEK 960,045 from SEK 30,547,844.50 to SEK 31,507,889.50, equivalent to about 3.0 percent of shares and votes in the Company after full exercise.

The fair value of the options was determined using the Black-Scholes model for each allotment made in 2008, 2009 and 2010. The data below has been used for the calculation. The data is presented in intervals taking into account the fact that allotment took place on several occasions in 2008, 2009 and 2010.

Employee stock option plan	2010	2009	2008
Allotted options	449,127	107,250	498,750
Fair value per option (SEK)	7.23	3.99–5.41	1.67–8.14
Share price for underlying shares (SEK)	27.60	20.50–23.60	14.80–24.60
Subscription price (SEK)	26.84	26.84	26.84
Estimated life of the option	2,85 years	3,42–3,67 years	3,92–4,42 years
Risk-free interest rate during the life of the option	1.66%	1.80–1.99%	1.83–4.70%
Assumed volatility	35%	35%	35%
Expected dividends	-	-	-
Wage costs in 2010 for employee stock option programme (SEK thousand)	1,758	258	1,612
Wage costs in 2009 for employee stock option programme (SEK thousand)		165	1,379

In 2010 wage costs for the employee stock option programme had a negative impact on operating profit of SEK 3,628 thousand (1,544). The programme expenses refer to both the estimated cost of the value of the employees' service during the period, valued at market value at the time of the allocation, and the portion of the estimated social security fees earned during the period. BioInvent will pay social security fees on the gain that may result from the exercise of the employee options, estimated as the difference between the subscription price of the employee stock option and the market value of the shares.

NOTE 3 Information about auditors' fees

SEK thousand	Group 2010	Group 2009	Parent company 2010	Parent company 2009
Ernst & Young				
Audit	198	170	198	170
Other auditing activity besides the audit	236	166	236	166
Tax advising	-	8	-	8
Other services	17	6	17	6
Total	**451**	**350**	**451**	**350**

NOTE 4 Depreciation according to plan of intangible and tangible fixed assets

SEK thousand	Group 2010	Group 2009	Parent company 2010	Parent company 2009
Research and development costs	8,740	10,651	8,740	10,651
Sales and administrative costs	632	466	632	466
Total	**9,372**	**11,117**	**9,372**	**11,117**

Depreciation of intangible and tangible assets is included in the items in the income statement as indicated above. Depreciation of intangible fixed assets amounted to SEK 3,970 thousand (5,362) and is included in the income statement item "Research and development costs."

NOTE 5 Operational leasing

Leasing charges are for laboratory, production and office premises. Leasing costs in 2010 and 2009 amounted to SEK 10,829 thousand (10,055) for the Group and the Parent company. The table below shows the minimum lease payments for non-cancellable operational leasing agreements.

SEK thousand	Group	Parent company
Payments due:		
Year 2011	10,049	10,049
Year 2012-2015	10,322	10,322
Year 2016 or later	-	-
Total	**20,371**	**20,371**

NOTE 6 Income statement classified according to type of cost

SEK thousand	Group 2010	Group 2009	Parent company 2010	Parent company 2009
External costs	113,801	167,281	113,801	167,281
Personnel costs	87,944	86,255	85,389	85,048
Depreciation	9,372	11,117	9,372	11,117
Total	**211,117**	**264,653**	**208,562**	**263,446**

NOTE 7 Exchange rate differences that affected profit/loss for the period

	Group		Parent company	
SEK thousand	**2010**	**2009**	**2010**	**2009**
Exchange rate differences that affected the operating profit/loss	-23	-709	-23	-709
Financial exchange rate differences	-1,498	340	-1,498	340
Total	**-1,521**	**-369**	**-1,521**	**-369**

NOTE 8 Interest income and similar items

	Group		Parent company	
SEK thousand	**2010**	**2009**	**2010**	**2009**
Interest income	941	2,501	941	2,501
Exchange rate differences	48	503	48	503
Total	**989**	**3,004**	**989**	**3,004**

NOTE 9 Interest costs and similar items

	Group		Parent company	
SEK thousand	**2010**	**2009**	**2010**	**2009**
Interest costs	-3	0	-3	0
Exchange rate differences	-1,546	-163	-1,546	-163
Total	**-1,549**	**-163**	**-1,549**	**-163**

NOTE 10 Tax on profit for the year

	Group		Parent company	
Tax on profit for the year	**2010**	**2009**	**2010**	**2009**
Current tax on profit for the year	0	0	0	0
Deferred taxes relating to temporary differences	0	0	0	0
Reported tax on the profit for the year	**0**	**0**	**0**	**0**

	Group		Parent company	
Reconciliation of effective tax	**2010**	**2009**	**2010**	**2009**
Reported profit/loss before tax	-128,400	-176,661	-125,845	-175,454
Tax according to the applicable tax rate, 26,3%	33,769	46,462	33,097	46,144
Tax effect of costs that are not deductible	-165	-200	-165	-200
Tax effect of loss carry forward for which the deferred tax claim has not been/shall be considered	-33,604	-46,262	-32,932	-45,944
Reported tax on profit/loss for the year	**0**	**0**	**0**	**0**

NOTE 11 Earnings per share

Earnings per share before dilution	2010	2009
Profit/loss for the period	-128,400	-176,661
Average number of outstanding shares (thousand)	60,522	55,661
Earnings per share before dilution, SEK	**-2.12**	**-3.17**

Earnings per share after dilution	2010	2009
Profit/loss for the period	-128,400	-176,661
Average number of outstanding shares (thousand)	61,542	55,661
Earnings per share after dilution, SEK	**-2.12**	**-3.17**

Earnings per share before dilution is based on profit/loss for the year attributable to Parent company shareholders and a weighted average of the number of outstanding shares.

Diluted earnings per share is based on profit/loss for the year attributable to Parent company shareholders and a weighted average of the number of outstanding shares plus the dilutive effects for potential shares. The subscription price of the 2008/2012 employee stock option programme is SEK 26.84 per share. An average share price of SEK 30.24 per share was used to determine whether a dilution effect exists for 2010. There is, however, no dilution of earnings per share because the earnings per share before dilution was negative.

NOTE 12 Intangible fixed assets

Acquired intangible fixed assets	Group		Parent company	
SEK thousand	2010	2009	2010	2009
Opening acquisition value	47,885	47,885	47,885	47,885
Acquisitions	-	-	-	-
Disposals	-	-	-	-
Closing accumulated acquisition value	**47,885**	**47,885**	**47,885**	**47,885**
Opening depreciation	-40,863	-35,501	-40,863	-35,501
Disposals	-	-	-	-
Depreciation for the year	-3,970	-5,362	-3,970	-5,362
Closing accumulated depreciation	**-44,833**	**-40,863**	**-44,833**	**-40,863**
Closing residual value according to plan	**3,052**	**7,022**	**3,052**	**7,022**

NOTE 13 Tangible fixed assets

Equipment	Group		Parent company	
SEK thousand	2010	2009	2010	2009
Opening acquisition value	76,008	77,355	76,008	77,355
Acquisitions	4,007	1,297	4,007	1,297
Disposals	-2,658	-2,644	-2,658	-2,644
Closing accumulated acquisition value	**77,357**	**76,008**	**77,357**	**76,008**
Opening depreciation	-64,326	-61,932	-64,326	-61,932
Disposals	2,658	2,644	2,658	2,644
Depreciation for the year	-5,244	-5,038	-5,244	-5,038
Closing accumulated depreciation	**-66,912**	**-64,326**	**-66,912**	**-64,326**
Closing residual value according to plan	**10,445**	**11,682**	**10,445**	**11,682**

Investments in rented premises	Group		Parent company	
SEK thousand	2010	2009	2010	2009
Opening acquisition value	10,967	10,967	10,967	10,967
Acquisitions	621	-	621	-
Closing accumulated acquisition value	**11,588**	**10,967**	**11,588**	**10,967**
Opening depreciation	-10,680	-9,963	-10,680	-9,963
Depreciation for the year	-158	-717	-158	-717
Closing accumulated depreciation	**-10,838**	**-10,680**	**-10,838**	**-10,680**
Closing residual value according to plan	**750**	**287**	**750**	**287**

Tangible fixed assets are primarily equipment used in research and development.
Investments in rented premises are primarily investments in rented production facilities.

NOTE 14 Shares in subsidiaries

	Co. reg. no.	Reg. office	Share of equity	Share of votes	Book value
BioInvent Finans AB	556605-9571	Lund	100%	100%	100

BioInvent Finans AB administers the warrants issued by BioInvent International AB.

NOTE 15 Prepaid expenses and accrued income

	Group		Parent company	
SEK thousand	2010	2009	2010	2009
Prepaid rent	1,801	2,684	1,801	2,684
Other items	3,113	3,694	3,113	3,694
Total	**4,914**	**6,378**	**4,914**	**6,378**

NOTE 16 Accrued expenses and deferred income

	Group		Parent company	
SEK thousand	**2010**	**2009**	**2010**	**2009**
Payroll liabilities	11,485	10,526	11,485	10,526
Social security fees	6,222	4,939	6,222	4,939
Other items	2,545	4,171	2,530	4,156
Total	**20,252**	**19,636**	**20,237**	**19,621**

NOTE 17 Financial instruments

FAIR VALUES

Below is a comparison of the reported values and the fair values of the Group's financial instruments.

	Book value		Actual value	
SEK thousand	**2010**	**2009**	**2010**	**2009**
Financial assets				
Loan receivables and accounts receivables				
Accounts receivables	4,377	3,441	4,377	3,441
Other receivables	7,706	11,863	7,706	11,863
	12,083	15,304	12,083	15,304
Available-for-sale financial assets				
Current investments	69,118	9,984	69,118	9,984
Current investments that constitute liquid funds	14,964	45,974	14,964	45,974
Cash and bank	21,988	28,062	21,988	28,062
	106,070	84,020	106,070	84,020
Financial assets carried at fair value through profit or loss for the year				
Derivatives	33	7	33	7
Total	**118,186**	**99,331**	**118,186**	**99,331**
Financial liabilities				
Other financial liabilities				
Accounts payables	-17,282	-16,510	-17,282	-16,510
Other liabilities	-26,305	-34,467	-26,305	-34,467
Accrued expenses	-20,252	-19,636	-20,252	-19,636
	-63,839	-70,613	-63,839	-70,613
Financial liabilities recognised at fair value through profit or loss for the year				
Derivatives	0	-14	0	-14
Total	**-63,839**	**-70,627**	**-63,839**	**-70,627**

NOTE 17 Financial instruments, continued

MATURITIES

Maturities for financial instruments are presented below

Remaining term, 31 Dec. 2010 SEK thousand	**On demand**	**< 3 months**	**3-12 months**	**Total**
Financial assets				
Loan receivables and accounts receivables				
Accounts receivables		4,377		4,377
(where of past due but not recognised as impairment losses)		(-)		(-)
Other receivables		7,706		7,706
Available-for-sale financial assets				
Current investments			69,118	69,118
Current investments that constitute liquid funds		14,964		14,964
Cash and bank	21,988			21,988
Financial assets carried at fair value through profit or loss for the year				
Derivatives		33		33
Total	**21,988**	**27,080**	**69,118**	**118,186**
Financial liabilities				
Other financial liabilities				
Accounts payables		-17,282		-17,282
Other liabilities		-26,305		-26,305
Accrued expenses		-20,252		-20,252
Financial liabilities recognised at fair value through profit or loss for the year				
Derivatives		0		0
Total	**-**	**-63,839**	**-**	**-63,839**
Remaining term, 31 Dec. 2009				
Financial assets	**28,062**	**61,285**	**9,984**	**99,331**
Financial liabilities	**-**	**-70,627**	**-**	**-70,627**

NET GAINS/LOSSES

Below are the net gains/losses for financial instruments recognised through profit or loss for the year.

SEK thousand	**2010**	**2009**
Financial assets		
*Loan receivables and accounts receivables**	-428	516
*Available-for-sale financial assets***	-1,498	340
Financial assets carried at fair value through profit or loss for the year	-	-
Financial liabilities		
*Other financial liabilities**	405	-1,225
Financial liabilities recognised at fair value through profit or loss for the year	**-**	**-**
Total	**-1,521**	**-369**

*Reported under "Other operating revenues and costs."

**Reported under "Profit/loss from financial investments."

The undersigned certify that the consolidated accounts and the annual report have been prepared in accordance with International Financial Reporting Standards (IFRS), as adopted for use in the European Union, and generally accepted accounting principles respectively, and give a true and fair view of the financial positions and results of the Group and the Company, and that the Directors' reports of the Group and the Company give a fair review of the development of the operations, financial positions and results of the Group and the Company and describes substantial risks and uncertainties that the Group companies faces.

Lund, 1 March 2011

Karl Olof Borg Chairman of the Board	Lars Backsell	Carl Borrebaeck	Lars Ingelmark
Elisabeth Lindner	Ulrika T Mattson	Björn Nilsson	Kenth Petersson

Svein Mathisen
President and CEO

Our audit report was submitted on 1 March 2011
ERNST & YOUNG AB

Johan Thuresson
Authorised Public Accountant

Audit report

To the annual meeting of the shareholders of BioInvent International AB (publ) Co. reg. no 556537-7263

We have audited the annual accounts, the consolidated accounts, the accounting records and the administration of the Board of Directors and the CEO of BioInvent International AB for the year 2010. The annual accounts and the consolidated accounts of the Company are included in the printed version of this document on pages 28-50. The Board of Directors and the CEO are responsible for these accounts and the administration of the Company as well as for the application of the Annual Accounts Act when preparing the annual accounts and the application of International Financial Reporting Standards IFRSs as adopted by the EU and the Annual Accounts Act when preparing the consolidated accounts. Our responsibility is to express an opinion on the annual accounts, the consolidated accounts and the administration based on our audit.

We conducted our audit in accordance with generally accepted auditing standards in Sweden. Those standards require that we plan and perform the audit to obtain reasonable assurance that the annual accounts and the consolidated accounts are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the accounts. An audit also includes assessing the accounting principles used and their application by the Board of Directors and the CEO and significant estimates made by the Board of Directors and the CEO when preparing the annual accounts and consolidated accounts as well as evaluating the overall presentation of information in the annual accounts and the consolidated accounts. As a basis for our opinion concerning discharge from liability, we examined significant decisions, actions taken and circumstances of the Company in order to be able to determine the liability, if any, to the Company of any Board member or the CEO. We also examined whether any Board member or the CEO has, in any other way, acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association. We believe that our audit provides a reasonable basis for our opinion set out below.

The annual accounts have been prepared in accordance with the Annual Accounts Act and give a true and fair view of the Company's financial position and results of operations in accordance with generally accepted accounting principles in Sweden. The consolidated accounts have been prepared in accordance with the International Financial Reporting Standards IFRSs as adopted by the EU and the Annual Accounts Act and give a true and fair view of the Group´s financial position and results of operations. The statutory administration report is consistent with the other parts of the annual accounts and the consolidated accounts.

We recommend to the Annual General Meeting that the income statement and balance sheet of the Parent company and the consolidated statement of comprehensive income and the consolidated statement of financial position for the Group be adopted, that the profit of the Parent company be dealt with in accordance with the proposal in the directors' report and that the members of the Board and the CEO be discharged from liability for the financial year.

Lund, 1 March 2011
Ernst & Young AB

Johan Thuresson
Authorised Public Accountant

Corporate governance report

BioInvent applies the Swedish Code of Corporate Governance ("the Code"). In addition to the Code, BioInvent also complies with applicable rules in the Swedish Companies Act, rules and recommendations ensuing from the Company's listing on NASDAQ OMX Stockholm, and good practices on the stock market.

This corporate governance report was prepared in compliance with the stipulations in the Annual Accounts Act and the Code. The corporate governance report has been prepared as a separate document from the annual report and as such is not part of the formal annual report documentation. The corporate governance report has been reviewed by the Company's auditor in accordance with the stipulations in the Annual Accounts Act. The auditor's statement is attached to the report.

Annual General Meeting

The Annual General Meeting (AGM), or where appropriate an extraordinary general meeting, is the decision-making body for BioInvent at which all shareholders can participate. The Articles of Association do not stipulate any restriction with respect to how many votes each shareholder may exercise at shareholders' meetings. The AGM considers the Company's progress and resolves on a number of key issues such as dividends, Directors fees, amendments to the Articles of Association, appointing auditors, discharge of the Board of Directors from liability, and the election of a new Board of Directors until the next Annual General Meeting. At the present time, an auditor for the Company and a substitute are elected every four years.

The AGM has not authorised the Board of Directors to decide on the issuance of new shares or the acquisition of treasury shares by the Company.

The 2010 Annual General Meeting was held on 20 April 2010 and the minutes are available on the BioInvent website. The Annual General Meeting 2011 will be held on Thursday 24 March at 4 p.m..

Notification to attend the AGM is published no earlier than six, and no later than four, weeks before the Meeting. Proposals to the Meeting should be addressed to BioInvent International AB, attn: Board of Directors, 223 70 Lund and submitted in good time before notification to attend the meeting is issued, no later than seven weeks before the meeting.

Nominating Committee

In accordance with the resolution of the Annual General Meeting, the Nominating Committee shall consist of the Chairman of the Board as the convenor, and a representative for each of the Company's three largest shareholders as of 31 August each calendar year. The Nominating Committee shall prepare all the elections and proposals of remuneration that come into question, from the Nominating Committee has been appointed until a new Nominating Committee is appointed. The Nominating committee is tasked with preparing proposals to present to the AGM regarding the election of Chairman of the General Meeting, Chairman of the Board and other Board members, board remuneration, shared among the Chairman, other Board members and possible compensation for committee work and, where applicable, election of auditors and auditor's fees.

The Nominating Committee for the 2010 Annual General Meeting comprised Lennart Hansson (Stiftelsen Industrifonden), Ulrica Slåne (Tredje AP-fonden fonden), Karin Lind-Mörnesten (Östersjöstiftelsen) and the Chairman of the Board Karl Olof Borg. The Nominating Committee formulated proposals for the chairman of the general meeting, and the composition of the Board of Directors, as well as explanations for these choices, along with directors' fees. The Nominating Committee had three meetings and a number of telephone calls. The Nominating Committee did not receive any remuneration.

The composition of the Nominating Committee for the 2011 Annual General Meeting was presented on the BioInvent website on 8 November 2010. According to the Code, the Company must post the names of the Nominating Committee's members on the Company's website six months prior to the Annual General Meeting and, where applicable, information on which shareholders the Committee members represent. Due to the fact that it has taken longer than anticipated to appoint the Nominating Committee, BioInvent has deviated from the above-named requirement. The 2011 Annual General Meeting will be held about a month earlier than the last year's AGM. The Nominating Committee for the 2011 Annual General Meeting consists of Tony Sandell (B&E Participation AB), Ulrica Slåne (Tredje AP-fonden), Jonas Lidholm (Sjätte AP-fonden) and the Chairman of the Board Karl Olof Borg. Proposals to the Nominating Committee should be addressed to Marie Serwe, by mail: BioInvent International AB (publ), SE-223 70 Lund or tel: +46 (0)46-46 286 85 50. The Nominating Committee has prepared proposals for the 2011 Annual General Meeting for the chairman of the general meeting and composition of the Board of Directors, along with explanations for these choices, as well as directors' fees. The Nominating Committee had three meetings and a number of telephone conversations. The Nominating Committee did not receive any remuneration.

The Board of Directors and its work

BioInvent's Board of Directors is elected annually at the AGM for the period until the next AGM and, according to the Articles of Association, is to consist of no fewer than five and no more than nine members. The Articles of Association do not contain specific stipulations on the appointment or dismissal of Board members or on amendments to the Articles of Association. The Board currently consists of eight AGM-elected directors and one employee representative. The 2010 AGM discharged the Board members and the President and CEO from liability and re-elected the Board members: Karl Olof Borg, Carl Borrebaeck, Lars Ingelmark, Elisabeth Lindner, Svein Mathisen, Björn Nilsson and Kenth Petersson. Lars Henriksson had declined re-election. The AGM elected Karl Olof Borg to be Chairman of the Board.

The Board of Directors is presented on page 60 of the 2010 annual report. CEO Svein Mathisen is on the Board of Directors. Carl Borrebaeck, member of BioInvent's Board of Directors, is employed as a senior scientific advisor for the Company. He does not work with BioInvent's operations in his capacity as scientific advisor. Other elected directors are independent, both in relation

to the major shareholders and in relation to the Company and senior management. Since no Company shareholders control 10 percent or more of the shares and are not therefore categorized as major shareholders, there can be no relationship of dependence between the AGM-elected directors and major shareholders. The 2010 AGM set the Board's fees at SEK 400,000 for the Chairman of the Board and SEK 160,000 for each of the other members of the Board not employed by the Company. In addition hereto, but not to the Chairman of the Board, it was decided that SEK 50,000 shall be the fee for the Chairman of the Audit Committee and SEK 40,000 shall be the fee for each of the other members in the Audit Committee and SEK 20,000 shall be the fee for each of the members in the Remuneration Committee.

The Board has two preparatory committees, the Remuneration Committee and the Audit Committee. The work of the Board is governed by rules of procedure that are revised and re-adopted by the Board at least once a year. The rules of procedure consist primarily of directions for the work of the Board, instructions for the division of duties between the Board and the CEO and instructions for financial reporting.

In 2010 the Board of Directors held eight regular meetings and three extra meetings. The Board of Directors met with the Company's auditor on two occasions, including one occasion without the presence of the CEO or other persons from senior management. Attorney Madeleine Rydberger, Mannheimer Swartling Advokatbyrå, served as the secretary of the Board during the year. Regular items on the agenda at the meetings included following up on the operation in relation to the Company's budget and strategic plan. In addition the Board has considered and resolved on issues pertaining to research and development, financing, intellectual property, strategic focus and planning, the budget, essential agreements, audits, financial reporting and compensation related issues. Once a year the Board conducts an evaluation of its work and the work of the CEO and this evaluation is provided to the Nominating Committee.

Board member	Attendance
Karl Olof Borg (Chairman)	11 (11)
Lars Backsell[1)]	5 (6)
Carl Borrebaeck	8 (11)
Lars Henriksson[2)]	5 (5)
Lars Ingelmark	10 (11)
Elisabeth Lindner	6 (11)
Svein Mathisen	11 (11)
Ulrika T Mattson	9 (11)
Björn Nilsson	8 (11)
Kenth Petersson	11 (11)

1) Elected on 20 April 2010 in connection with the 2010 AGM

2) Resigned on 20 April 2010 in connection with the 2010 AGM

Remuneration Committee

The Board has appointed a remuneration committee consisting of Chairman of the Board, Karl Olof Borg, as well as two other Directors, Lars Henriksson and Elisabeth Lindner. Lars Henriksson resigned from the Board on 20 April 2010 and was replaced on the Remuneration Committee by Lars Backsell who was elected as a new director at the AGM. All directors are independent of the Company and its senior management.

The Board's Remuneration Committee, whose work is regulated in the instructions that comprise part of the rules of procedure for the Board of Directors, considers and decides on issues pertaining to remuneration and benefits to all senior executives except the CEO, whose compensation is decided by the Board of Directors. The committee also prepares other remuneration issues of greater importance, such as incentive programmes. Furthermore, the Remuneration Committee is tasked with monitoring and evaluating variable remuneration for senior executives paid out or discontinued during the year, and monitoring and evaluating the application of the guidelines for remuneration for senior executives which the AGM is required by law to vote on, as well as applicable remuneration structures and levels within the Company. The Remuneration Committee reports to the Board of Directors. The Committee met three times in 2010.

Member of the Remuneration Committee	Attendance
Karl Olof Borg (Chairman)	3 (3)
Lars Backsell[1)]	0 (1)
Lars Henriksson[2)]	2 (2)
Elisabeth Lindner	2 (3)

1) Elected on 20 April 2010 in connection with the 2010 AGM

2) Resigned on 20 April 2010 in connection with the 2010 AGM

Audit Committee

The Board of Directors has appointed an Audit Committee consisting of Björn Nilsson (Chairman), Karl Olof Borg, Lars Ingelmark and Kenth Petersson. All directors are independent of the Company, its senior management, and major shareholders. The Audit Committee's members have the requisite accounting expertise.

The Audit Committee, whose work is regulated in the instructions that serve as part of the rules of procedure for the Board of Directors, is tasked with preparing issues on behalf of the Board of Directors pertaining to selection of auditors and remuneration, follow up of the auditors' work and the Company's internal control systems, follow up of the current risk scenario, follow up of external audits and the Company's financial information, adoption of the earnings report for quarters 1 and 3, preparation of the interim report for quarters 2 and 4, as well as the Company's annual report, follow up of issues pertaining to financing, and preparations to adopt and revise financial policy and other issues that the Board of Directors entrusts to the Committee. The Audit Committee reports to the Board of Directors. The committee held five meetings in 2010.

Member of the Audit Committee	Attendance
Björn Nilsson (Chairman)	5 (5)
Karl Olof Borg	5 (5)
Lars Ingelmark	5 (5)
Kenth Petersson	5 (5)

Auditors

According to the Articles of Association, BioInvent is to appoint at least one and no more than three auditors for a term as prescribed by law. The auditor attends at least one Board meeting a year not attended by the CEO and other members of the Company's senior management. The 2008 Annual General Meeting elected Ernst & Young AB to serve as the Company's auditors for the period until the end of the Annual General Meeting held during the fourth financial year after the auditors were elected, which is 2012. Johan Thuresson, authorised public accountant, is principal auditor.

Group Management

According to its guidelines and instructions, the Board of Directors has delegated day-to-day management to CEO Svein Mathisen. The CEO and under his leadership, other members of the management group, are responsible for collective business operations and day-to-day management. The CEO reports regularly to the Board of Directors on the Company's business operations, financial performance and other issues relevant to the company. The CEO and senior management are presented on page 61 of the 2010 annual report.

Remuneration to senior executives

The 2010 Annual General Meeting adopted guidelines for remuneration to senior executives. According to the guidelines, salaries and other terms of employment for senior management are set at market rates. In addition to a stable base salary senior executives can also receive a variable salary, which will be limited and based mainly on technical and commercial milestones within proprietary drug projects. Senior executives may also receive remuneration in the form of options or other share-related incentive programmes, as decided by the Annual General Meeting of shareholders. The complete guidelines can be seen in the Board of Directors' Report on page 32.

The Company's systems for internal control and risk management with respect to financial reporting for the 2010 financial year

According to the Swedish Companies Act and the Swedish Code of Corporate Governance the Board is responsible for internal control. This description was prepared according to the Annual Accounts Act, chapter 6 § 6, and describes the Company's systems for internal control in connection with financial reporting.

Internal control over financial reporting is a process designed by the Board of Directors to provide the Board, senior management and others involved in the organisation with reasonable assurance regarding the reliability of external financial reporting and the extent to which the financial statements are formulated in compliance with generally accepted accounting principles, applicable laws and regulations as well as other requirements for listed firms.

Control Environment

The foundation of the internal control process consists of the overall control environment: the Company's ethical values, organizational structure and decision-making procedures, as well as the allocation of powers and responsibilities. The most essential components of the control environment at BioInvent are documented in its policies and other governing documents. BioInvent's rules of procedure describe the allocation of responsibilities between the Board of Directors and the CEO, as well as among the Board's committees. Other policies and governing documents include the Company's ethical guidelines, treasury policy and authorisation instructions.

Control activities

Control activities are necessary for senior management of the essential risks associated with the internal control process. To ensure the efficacy of its internal control procedures, BioInvent has both computerized controls in IT systems to handle authorisation and approval authority, as well as manual controls such as inventories and reconciliation procedures. Detailed financial analyses of the Company's performance, as well as follow-up of plans and forecasts, supplement the controls and provide an overall confirmation of the quality of financial reporting.

Information and communications

BioInvent's most essential policies and other governing documents are updated regularly and communicated to everyone involved through established information channels, in print and/or in electronic format.

Follow-up

BioInvent follows up and assesses its compliance with internal policies and other policy documents on a regular and annual basis. Suitability and functionality are also evaluated on a regular and annual basis. Inadequacies are reported and remedied in accordance with specific established procedures.

Internal audit

BioInvent has formulated governance and internal control systems with regular follow-up of compliance at various levels within the Company. The Board of Directors therefore does not consider a separate audit function to be necessary in the current situation. This is re-considered annually by the Board of Directors.

Lund, 1 March 2011
The Board of Directors

Auditor's report on the corporate governance statement

To the annual meeting of the shareholders of BioInvent International AB (publ) Co. reg. no 556537-7263

Engagement and responsibility

We have audited the corporate governance statement for the year 2010 on pages 52 – 54. It is the Board of Directors who is responsible for the corporate governance statement and that it has been prepared in accordance with the Annual Accounts Act. Our responsibility is to express an opinion on the corporate governance statement based on our audit.

The scope of the audit

We conducted our audit in accordance with FAR's auditing standard RevU 16 The auditor's examination of the corporate governance statement. That standard requires that we have planned and performed the audit to obtain reasonable assurance that the corporate governance statement is free of material misstatements. An audit includes examining, on a test basis, evidence supporting the information included in the corporate governance statement. We believe that our audit procedures provide a reasonable basis for our opinion set out below.

Opinion

In our opinion, the corporate governance statement has been prepared and is consistent with the annual accounts and the consolidated accounts.

Lund, 1 March 2011

Ernst & Young AB

Johan Thuresson
Authorised Public Accountant

The BioInvent share



BioInvent has been listed on NASDAQ OMX Stockholm since 2001.

Price trend and trading volume

In 2010, the share price increased 17%, from SEK 25.40 to SEK 29.70. During 2010 the OMX Stockholm_PI increased 23 % and OMX Stockholm Biotechnology_PI increased 40 %. The highest price paid in 2010 was SEK 39.60 and the lowest price was SEK 24.20. BioInvent's market capitalization totalled SEK 1,815 million at the end of 2010.

During the year 55.3 (48.9) million BioInvent shares were traded for a value of SEK 1,691 (1,186) million. This corresponds to a rate of turnover of 91% (90). Average trading volume per trading day was 218,607 (194,923) shares for a value of SEK 6.7 (4.7) million. Average number of trades per trading day were 253 (177).

Largest shareholders, 31 December 2010

Shareholders	No. of shares	Percentage of capital and votes
JP Morgan Bank	4,762,880	7.8
B&E Participation AB	3,913,000	6.4
Avanza Pension Försäkring	3,070,379	5.0
Nordnet Pensionsförsäkring	3,043,500	5.0
Staffan Rasjö	2,591,714	4.2
DnB NOR fonder	2,149,984	3.5
Länsförsäkringar fonder	1,855,496	3.0
Tredje AP-fonden	1,591,740	2.6
SEB Life Assurance	1,405,400	2.3
Sjätte AP-fonden	1,268,718	2.1
Mikael Lönn	1,200,000	2.0
Carl Borrebaeck*	1,142,908	1.9
Holberg fonder	1,100,300	1.8
Svein Mathisen*	1,050,000	1.7
Cristina Glad*	1,043,301	1.7
Friends Provident international	1,004,770	1.6
Other shareholders	28,901,599	47.3
Total	**61,095,689**	**100.0**

*Board member or part of Senior management

Ownership structure

In 2010, the number of shareholders increased 5%, from 6,650 to 7,004. Foreign owners held 30% (36) of the share capital and votes. The ten largest shareholders owned 42% (40) of the shares. About 71% (72) of the shareholders owned 1,000 or fewer shares each.

Analysts covering BioInvent

Peter Östling, Klas Palin – Redeye, Stockholm
Erik Hultgård – ABG Sundal Collier, Stockholm
Camilla Oxhamre – D. Carnegie, Stockholm
Gustaf Vahlne – Enskilda Securities, Stockholm
Alexander Weiss – Remium AB, Stockholm
Sten Westerberg, Yilmaz Mahshid – E. Öhman J:or Fondkommission, Stockholm
Olav Zilian– Helvea SA, Geneva

Share capital

As of 31 December 2010 the Company's share capital amounted to SEK 30.5 million distributed between 61,095,689 shares. Assuming that all options 1,920,090 issued due to the 2008/2012 employee stock option programme are exercised, the number of shares will be 63,015,779.

In February 2010 BioInvent implemented a directed share issue setting aside the shareholders' preferential rights with a total of 5,434,800 shares. SEK 144,4 thousand was raised after issue expenses.

There is only one class of share. Each share entitles the holder to one vote at shareholders' meetings and all shares carry equal rights to the Company's assets and profit.

Employee incentive programme

The annual general meeting on 14 April 2008 resolved to adopt an incentive programme comprising a maximum of 1,450,000 employee options (Sw. personaloptioner) and to issue 1,920,090 warrants for the subsidiary BioInvent Finans AB, free of charge, to secure the company's commitment under the incentive programme and to cover the company's associated social security contributions. BioInvent Finans AB has subscribed all the warrants. Each employee option entitles the holder to subscribe to a new share at a subscription price of SEK 26.84. A basic allocation of 513,750 employee options took place during 2008 and 2009.

Extra allotment of 69,750 employee options took place in February 2009, an extra allotment of 429,750 employee options took place in January 2010 and in February 2011 with 37,875 employee options.

The annual general meeting on 21 April 2009 resolved to adopt an amendment to the existing employee options programme 2008/2012, resolved by the AGM 2008. The amendment programme comprise a maximum of 240,250 employee options, directed to the employees of the Company, entitling the holder to subscribe for new shares. Each employee option entitles the holder to subscribe to a new share at a subscription price of SEK 26.84. A basic allocation of 33,750 employee options took place during 2009 and 2010. Extra allotment of 8,127 employee options took place in January 2010.

Dividend and dividend policy

The Board of Directors do not recommend payment of any dividend for the 2010 financial year. The Company will continue to focus on research and development of new products. Available financial resources will be used to finance these projects. The Board of Directors therefore do not recommend that any dividend be paid for the next few years.

Distribution of financial reports

Annual reports will be sent to shareholders upon request and may be ordered at the address BioInvent international AB, 223 70 Lund, or by fax +46 (0)46-211 08 06, or telephone +46 (0)46-286 85 50, or by e-mail info@bioinvent.com. The annual report is published in Swedish and English.

Upcoming financial information

Interim reports: 14 April, 14 July, 13 October 2011
Financial statement 2011: 9 February 2012

Share statistics, 31 December 2010

Size of holdings	No. of shareholders	No. of shareholders, %	No. of shares in %
1–500	3,643	52.0	1.2
501–1 000	1,329	19.0	2.0
1 001–2 000	818	11.7	2.3
2 001–5 000	604	8.6	3.6
5 001–10 000	272	3.9	3.5
10 001–20 000	133	1.9	3.4
20 001–50 000	97	1.4	5.2
50 001–100 000	40	0.6	5.2
100 001–500 000	48	0.7	19.8
500 001–1 000 000	7	0.1	9.5
1 000 001–5 000 000	13	0.2	44.3
Total	**7,004**	**100.0**	**100.0**

Changes in the share capital

Year		Transaction capital, SEK	Increase in share no. of shares	Increase in SEK	Share capital, no. of shares	Ratio value
1996	BioInvent International AB was founded[1)]			100,000	10,000	10.00
1997	New share issue	7,140	714	107,140	10,714	10.00
1997	Bonus issue	857,120	85,712	964,260	96,426	10.00
1998	Share split 1:10		867,834	964,260	964,260	1.00
1998	New share issue[2)]	181,000	181,000	1,145,260	1,145,260	1.00
1999	New share issue[3)]	108,527	108,527	1,253,787	1,253,787	1.00
2000	New share issue[4)]	250,000	250,000	1,503,787	1,503,787	1.00
2000	Warrants exercised	11,013	11,013	1,514,800	1,514,800	1.00
2001	Bonus issue	9,846,200		11,361,000	1,514,800	7.50
2001	Share split 1:15		21,207,200	11,361,000	22,722,000	0.50
2001	Warrants exercised	461,152.5	922,305	11,822,152.5	23,644,305	0.50
2001	New share issue[5)]	2,250,000	4,500,000	14,072,152.5	28,144,305	0.50
2002	New share issue[6)]	665,625.5	1,331,251	14,737,778	29,475,556	0.50
2005	New share issue[7)]	8,842,666.5	17,685,333	23,580,444.5	47,160,889	0.50
2007	New share issue[8)]	4,250,000	8,500,000	27,830,444.5	55,660,889	0.50
2010	New share issue[9)]	2,717,400	5,434,800	30,547,844.5	61,095,689	0.50

1) BioInvent International AB was established by its managers, Stiftelsen Industrifonden, Pronova a.s. and Aragon Fondkommission.

2) In November 1998 the Company issued 181,000 new shares aimed at institutional investors. The issue price was SEK 125 and SEK 22.6 million was raised for BioInvent International AB after issue cost deductions.

3) In November 1999 the Company issued 108,527 new shares aimed at institutional investors. The issue price was SEK 175 and SEK 18.7 million was raised for BioInvent International AB after issue cost deductions.

4) In March 2000, the Company issued 250,000 shares aimed at institutional investors. The issue price was SEK 720 and SEK 169.0 million was raised for BioInvent International AB after issue cost deductions.

5) New share issue in connection with the listing. The issue price was SEK 62 and SEK 261.6 million was raised for BioInvent International AB after issue cost deductions.

6) In March 2002, the Company carried out a directed issue of 1,331,251 new shares for Oxford GlycoSciences. The issue price was SEK 39 and this raised SEK 52.0 million for BioInvent International AB. There were no issue costs.

7) In November 2005 the Company carried out a new share issue. The issue price was SEK 9 and SEK 146.2 million was raised for BioInvent International AB after deductions of issue costs.

8) In July 2007 the Company carried out a directed issue. The issue price was SEK 14.75 and SEK 120.0 million was raised for BioInvent International AB after deductions of issue costs.

9) In February 2010 the Company carried out a directed issue. The issue price was SEK 27.60 and SEK 144.4 million was raised for BioInvent International AB after deductions of issue costs.

Five-year review

INCOME STATEMENT, SEK MILLION	2010	2009	2008	2007	2006
Net revenues	82.9	80.7	252.1	143.4	50.8
Research and development costs	-178.9	-229.2	-215.4	-140.9	-135.4
Sales and administrative costs	-32.2	-35.5	-30.9	-28.7	-29.8
Other operating revenues and costs	0.4	4.5	0.7	2.7	2.6
	-210.7	-260.2	-245.6	-166.9	-162.6
Operating profit/loss	**-127.8**	**-179.5**	**6.6**	**-23.4**	**-111.7**
Profit/loss from financial investments	-0.6	2.8	9.7	7.4	2.9
Profit/loss after financial items	**-128.4**	**-176.7**	**16.3**	**-16.1**	**-108.8**
Tax on profit for the year	–	–	–	–	–
Profit/loss for the year	**-128.4**	**-176.7**	**16.3**	**-16.1**	**-108.8**

BALANCE SHEET, SEK MILLION	2010	2009	2008	2007	2006
Intangible fixed assets	3.1	7.0	12.4	12.5	18.9
Tangible fixed assets	11.2	12.0	16.4	14.2	16.2
Inventories	0.7	2.0	2.3	3.8	7.8
Current receivables	17.0	21.2	51.9	23.6	17.4
Current investments and liquid funds	106.1	84.0	212.5	216.9	88.0
Total assets	**138.0**	**126.2**	**295.4**	**271.0**	**148.3**
Shareholders' equity	74.2	55.6	231.3	214.1	110.2
Non-interest-bearing liabilities	63.8	70.6	64.1	56.9	38.2
Interest-bearing liabilities	–	–	–	–	–
Total shareholders' equity and liabilities	**138.0**	**126.2**	**295.4**	**271.0**	**148.3**

CASH FLOW, SEK MILLION	2010	2009	2008	2007	2006
Operating profit/loss	-127.8	-179.5	6.6	-23.4	-111.7
Adjustments for depreciation, interest and other items	12.6	17.0	21.5	18.3	18.3
Changes in working capital	-2.4	35.3	-18.8	17.8	-4.9
Cash flow from current operations	**-117.7**	**-127.1**	**9.2**	**12.6**	**-98.3**
Cash flow from investment activities	-4.6	-1.3	-13.6	-3.9	-9.0
Cash flow from current operations and investment activities	**-122.3**	**-128.4**	**-4.4**	**8.7**	**-107.3**
Cash flow from financing activities	144.4	-	-	120.1	-
Increase/decrease in current investments and liquid funds	**22.1**	**-128.4**	**-4.4**	**128.8**	**-107.3**

KEY FINANCIAL RATIOS	2010	2009	2008	2007	2006
Net revenue growth, %	2,7	-68,0	75,8	182,2	80,3
Net working capital, SEK million	-46,1	-47,4	-10,0	-29,4	-13,0
Net working capital/net revenue, %	-55,7	-58,7	-4,0	-20,5	-25,5
Operating capital, SEK million	-31,9	-28,4	18,8	-2,7	22,1
Operating capital/net revenue, %	-38,5	-35,2	7,5	-1,9	43,6
Capital employed, SEK million	74,2	55,6	231,3	214,1	110,2
Capital employed/net revenue, %	89,5	69,0	91,7	149,3	216,7
Shareholders' equity, SEK million	74,2	55,6	231,3	214,1	110,2
Return on shareholders' equity, %	-197,8	-123,1	7,3	-9,9	-66,1
Return on capital employed, %	-197,8	-123,1	7,3	-9,9	-66,1
Capital turnover, times	1,3	0,6	1,1	0,9	0,3
Equity/assets ratio, %	53,7	44,1	78,3	79,0	74,3
Intangible fixed assets investments, SEK million	-	-	6,0	-	-
Tangible fixed assets investments, SEK million	4,6	1,3	7,6	3,9	9,0
Average number of employees	96	105	99	96	96
Net revenue per employee, SEK million	0,9	0,8	2,5	1,5	0,5

DATA PER SHARE	2010	2009	2008	2007	2006
Earnings per share, SEK					
Before dilution	-2,12	-3,17	0,29	-0,31	-2,31
After full dilution	-2,12[1)]	-3,17[1)]	0,29[3)]	[2)]	-2,31[1)]
Shareholders' equity per share, SEK					
Before dilution	1,21	1,00	4,15	3,85	2,34
After full dilution	1,19	1,00[3)]	4,15[3)]	[2)]	2,34[3)]
Cash flow per share, SEK	-2,02	-2,31	-0,08	0,17	-2,28
Average no. of shares					
Before dilution (thousands)	60 522	55 661	55 661	51 175	47 161
After full dilution (thousands)	61 542	55 661[3)]	55 661[3)]	[2)]	47 161[3)]
Number of shares at end of period					
Before dilution (thousands)	61 096	55 661	55 661	55 661	47 161
After full dilution (thousands)	62 151	55 661[3)]	55 661[3)]	[2)]	47 161[3)]
Share price, 31 December, SEK	29,70	25,40	14,80	18,60	10,80

1) There is no dilution of earnings per share because the earnings per share before dilution was negative.
2) At the end of the period there were no outstanding warrants or employee options.
3) No dilution is present since the subscription price exceeds the average share price.

The figures in the tables are rounded to one decimal, while the calculations are made using a greater number of decimals. As a result, it may appear that certain tables do not add up.

DEFINITIONS

Net working capital
Non-interest-bearing current assets less non-interest-bearing current liabilities.

Operating capital
The balance sheet total less non-interest-bearing liabilities, other non-interest-bearing provisions and current investments and liquid funds.

Capital employed
The balance sheet total less non-interest-bearing liabilities and non-interest-bearing provisions.

Return on shareholders' equity
Profit/loss after financial items as a percentage of the average shareholders' equity.

Return on capital employed
Profit/loss after financial items plus financial costs as a percentage of average capital employed.

Capital turnover
Net revenue divided by the average capital employed.

Equity/assets ratio
Shareholders' equity as a percentage of the balance sheet total.

Average number of employees
Weighted average number of employees during the year.

Earnings per share
Profit/loss after financial items divided by the average number of shares.

Shareholders' equity per share
Shareholders' equity divided by the number of shares at the end of the period.

Cash flow per share
Cash flow from current operations and investment activities divided by the average number of shares.

The Board and Auditors

Karl Olof Borg

Chairman of the Board
Doctor of Pharmacy. Born 1941. Lives in Trosa, Sweden. Previously Vice President of Research at Astra AB, Pharmacia AB and Active Biotech AB. Member of the Board since 2001. Chairman of the Board since 2007. Chairman of the Remuneration Committee and member of the Audit Committe.

Other board appointments: Member of the Boards of Galenica AB, Alligator Bioscience AB and Biocrine AB.

Shareholding: 8,000

Lars Backsell

B Sc Economics at SSE and has completed AMP at Insead. Born 1952. Lives in Stockholm, Sweden. Previous roles include CEO of Recip AB and senior positions within Pharmacia AB and Coloplast A/S. Member of the Royal Swedish Academy of Engineering Sciences. Member of the Board since 2010. Member of the Remuneration Committee.

Other board appointments: Chairman of the Board of Recipharm AB and member of the Board of Lund University Bioscience AB.

Shareholding: 3,913,000 (through companies)

Carl Borrebaeck

Doctor of Science. Born 1948. Lives in Lund, Sweden. Deputy Vice-Chancellor at Lund University, Professor at the Department of Immunotechnology and Centre Director for the translational cancer centre – CREATE Health, Lund. Member of the Royal Swedish Academy of Engineering Sciences. Senior Scientific Advisor to the Company. Member of the Board since 1997.

Other board appointments: Chairman of the Boards of Lund University Innovation System AB and Immunovia AB. Member of the Boards of Alligator Bioscience AB, Lund University Bioscience AB and WntResearch AB.

Shareholding: 1,142,908

Lars Ingelmark

Bachelor of Medicine. Born 1949. Lives in Halmstad, Sweden. Head of Business Area Life Science of Sjätte AP-fonden. Member of the Board since 2006. Member of the Audit Committee.

Other board appointments: Chairman of the Boards of Gyttorp AB, SLS Invest AB, MoMail AB and Svensk Våtmarksfond. Member of the Boards of Innoventus AB, Innoventus Project AB, KA Intressenter AB, Svenska Jägareförbundet, Healthcare Göteborg AB and Skedala Säteri AB. Member of the Board and CEO of IQQU Styrelseutveckling AB.

Shareholding: -

Elisabeth Lindner

Master of Science, MBA. Born 1956. Lives in Stockholm, Sweden. CEO and President of Diamyd Medical AB. Member of the Royal Swedish Academy of Engineering Sciences. Member of the Board since 2005. Member of the Remuneration Committee.

Other board appointments: Chairman of the Board and CEO of Biosource Europe AB. Member of the Boards of Diamyd Therapeutics AB, Diamyd Diagnostics AB, Diamyd Inc and SwedenBIO.

Shareholding: 6,400

Svein Mathisen

President and CEO
Master of Science, Engineering Physics. Born 1956. Lives in Malmö, Sweden. President and CEO since 1997. Previously held senior positions within the Norsk Hydro Group. Member of the Board since 2001.

Other board appointments: Chairman of the Board of Biotec Pharmacon ASA and member of the Boards of Camurus AB and SwedenBIO.

Shareholding: 1,050 000
Employee options: 24,000

Ulrika T Mattson

Employee representative
University degree in Biomedical Laboratory Science. Born 1968. Lives in Malmö, Sweden. Biomedical Scientist. Member of the Board since 2007.

Other board appointments: -

Shareholding: 400 (own and affiliated holdings)
Employee options: 7,500

Björn Nilsson

Doctor of Science. Born 1956. Lives in Sollentuna, Sweden. Professor, CEO and member of the Royal Swedish Academy of Engineering Sciences. Associate professor at the Royal Institute of Technology (KTH) in Stockholm. Member of the Board since 1999. Chairman of the Audit Committe.

Other board appointments: Member of the Board of ÅF. Vice Chairman of the Board of ÅForsk.

Shareholding: 10,000

Kenth Petersson

Bachelor of Arts. Born 1956. Lives in Stockholm, Sweden. Member of the Board since 1997. Member of the Audit Committee.

Other board appointments: Chairman of the Boards of AlphaBeta AB, Biocrine AB, Diabetes Tools AB, Spiber Technologies AB and Science Pacific AB. Member of the Board of Alligator Bioscience AB.

Shareholding: 80,000

Auditors
Ernst & Young AB
Auditor in charge: Johan Thuresson, Authorised Public Accountant. Born 1964. Lives in Höllviken, Sweden. Auditor for BioInvent International AB since 2008.

Senior management

Svein Mathisen

President and CEO
Master of Science, Engineering Physics. Born 1956. Lives in Malmö, Sweden. President and CEO since 1997. Previously held senior positions within the Norsk Hydro Group. Member of the Board since 2001.

Other board appointments: Chairman of the Board of Biotec Pharmacon ASA and member of the Boards of Camurus AB and SwedenBIO.

Shareholding: 1,050 000
Employee options: 24,000

Björn Frendéus

Vice President, Preclinical Research
Doctor of Immunology. Born 1973. Lives in Landskrona, Sweden. Employed since 2001. Graduated as the nation´s first student from the Swedish Foundation for Strategic Research funded Biomedicine programmes within the Infection & Vaccinology programme in 2001.

Shareholding: 740 (own and affiliated holdings)
Employee options: 44,250

Cristina Glad

Executive Vice President
Doctor of Science, Biochemistry, MBA. Born 1952. Lives in Malmö, Sweden. Employed in 1987 by the former subsidiary Bioinvent Production AB. Member of the Royal Swedish Academy of Engineering Sciences. Member of the Boards of Ideonfonden AB and Lund University, Faculty of Medicine.

Shareholding: 1,043,301
Employee options: 24,000

Steven Glazer

Senior Vice President, Development
Doctor of Medicine. Born 1948. Lives in Copenhagen, Denmark. Employed since 2004. 2001-2004 Medical Director and Director of Development at Maxygen A/S, Denmark. Previously employed at NovoNordisk A/S etc.

Shareholding: -
Employee options: 46,500

Per-Anders Johansson

Vice President, Quality Assurance and Regulatory Affairs
Master of Science, Chemistry. Born 1955. Lives in Lund, Sweden. Employed in 1984 by the former subsidiary Bioinvent Production AB.

Shareholding: 250,000
Employee options: 24,000

Martin Wiles

Senior Vice President, Business Development
Ph. D. Chemistry, MBA. Born 1963. Lives in London, Great Britain. Employed since 2003. 1999-2003 Head of Business Development at KS Biomedix Holdings Plc, listed on the London Stock Exchange.

Shareholding: -
Employee options: 46,500

Glossary

Administer drugs To give drugs to patients, e.g. by injection.

Angiogenesis Formation of new blood vessels.

Antigen A substance that is foreign to the body and that can stimulate the immune system.

Anticoagulants Drugs that reduce the blood's ability to coagulate that are used, for example, to prevent blood clots from forming.

Antibody Reaction product in the body induced by antigens. Antibodies are proteins from the group collectively called immunoglobulins and can now be produced in laboratories.

Atherosclerosis Condition where deposits of fats and minerals form on the walls of large blood vessels.

Biological drugs Drugs, e.g. antibodies, with varying biological origins, including vaccines, blood products, cells, gene therapy, tissue and recombinant proteins. Recombinant proteins are produced from living cells.

Blockbuster A drug with sales of at least USD 1 billion a year.

Cell line Cultured cells with the same genetic origin.

Clinical trials Studies carried out on humans to test the effect and safety of future drugs.

DNA Deoxyribonucleic acid. The chemical material in a cell that contains the genetic code; genetic make-up.

Drug candidate/product candidate A substance with the potential to be developed into a drug.

Embolism When part of a blood clot breaks loose and is transported by the blood flow through the heart and elsewhere in the body, e.g. to the lungs.

Endothelial cells Cells that line the inside of blood vessels.

Enzyme A substance that triggers and stimulates chemical reactions in living organisms.

Fermentor A reactor where microorganisms are cultivated.

Genetic make-up All of the genetic material in a cell or an individual.

Genome See above.

GMP Good Manufacturing Practice. A set of instructions for manufacturing pharmaceuticals and ensuring their quality and safety.

Heparin Drug that impedes the coagulation of the blood.

Homologous Here, proteins with similar functions.

Human antibodies Antibodies that are perceived by the immune system as human.

Immunology Study of the origins and consequences of immune responses (i.e. antibody and cell responses).

Inflammation Reactive condition of tissue -following damage to the tissue or infection.

Inhibitory Inhibits a physiological process.

In vitro Within a test tube or another artificial environment -(opposite of in vivo).

In vivo "Within the living body." In biomedicine, something that is done to a living organism. In everyday speech, synonymous with experiments on animals.

LDL Transport molecule for blood lipids Commonly known as "the bad cholesterol."

Lipids Collective term for naturally occurring organic compositions that are not soluble in water, e.g. steroids, prostaglandins, fats and wax.

Lipoprotein Chemical compounds of proteins that transport lipids in the blood. They can be divided, for example into HDL and LDL.

Lymphoma Disease involving a tumor in the lymphoid tissue.

Macula degeneration/oedema Breakdown or accumulation of fluid in macula, i.e. "yellow spots" in the retina.

Mediate To bridge or transfer.

Metabolism All of the biochemical reactions that take place in living organisms.

Milestone payment Payment when targets are reached in a drug development project; often linked to the successful implementation of phases in clinical development.

OxLDL Oxidized LDL. A substance that can contribute to blood clots or infarction; a target protein for the development of a treatment for atherosclerosis.

Pathological Diseased, abnormal, changed by disease.

Phage Virus that can infect bacteria.

Phage display Technology for expressing molecules, e.g. -antibodies, on the surface of phages.

Pharmaceutical Referring to drugs or their preparation.

Pharmacokinetic How a drug is absorbed, distributed, broken down and excreted from the body.

Pharmacy The science of preparing and making drugs.

PIGF Growth factor that is secreted by tumor cells; target protein for one of BioInvent's anti-angiogenesis projects.

Plaque Deposits of substances/materials, for example on vessel walls.

Pre-clinical development Testing and documentation of a drug candidate's properties in a model system.

Protein The most important components in all organisms. There are many thousands of different proteins.

Pulmonary hypertension Elevated blood pressure in the pulmonary circulation.

Receptor Here, molecules on the surface of or inside cells that have the task of receiving and transferring signals.

Resistance The ability of e.g. tumor cells to avoid treatment that was originally effective. Resistance is developed when genes change and vary and the inhibitor therapy favours the variations that survive and multiply.

Retinopathy Medical term for a disease of the retina.

Royalty Payment linked to the sale of a drug; often a percentage of sales.

Screening Searching and final selection of the antibody fragments that bind the best to a given antigen.

Selection Selection of a number of possible antibody fragments that bind to a given antibody.

Specificity The ability of antibodies to recognise the 'right' -antigen and ignore all others.

Statins A group of antibodies that reduce the level of cholesterol in the blood.

Stroke Blood clot in the brain.

Safety study Study of side effects in animal models to ensure that a product is safe enough to begin clinical trials.

Target protein The proteins in the body upon which a drug can have an effect. An antigen can be a target protein upon which antibodies can have a therapeutic effect.

Therapeutic antibody Antibody that is used for the treatment of a disease; antibody-based drug.

Therapy Treatment; here in general with drugs.

Thrombosis Formation of a blood clot.

Toxicology Scientific study of poisons and their effects.

Toxin, toxic Toxic substance, with toxic effect.

Vaccine A medicine that is used in immunisation (vaccination) to produce protection against a disease that is often caused by an infection.

Validation Assessment of an antibody or target structure to -discover if they have the desired effect or characteristics.

Vascular That belongs to or has a connection with an organism's vascular system.

Vascular leakage Pathological condition characterised by leakage of cells and fluid from vessels.

VEGF inhibitor Substance that inhibits angiogenesis, where this is caused by the growth factor VEGF.

Annual General Meeting

The Annual General Meeting will be held on Thursday 24 March 2011 at 4 p.m., Elmdalavägen 16, Lund. Notice to attend will be announced in the Swedish press in Post- och Inrikes Tidningar and on the Company's website.

Shareholders wishing to attend the AGM must be registered in the shareholders' register kept by the Swedish Securities Register Centre (Euroclear) no later than Friday 18 March 2011 and must inform BioInvent of their intention to attend no later than 4 p.m. on Friday 18 March 2011 by sending a letter to: Sölvegatan 41, SE-223 70 Lund, attn: Marie Serwe, or by fax to +46 (0)46 211 08 06, or by phone +46 (0)46 286 85 50, or by e-mail to marie.serwe@bioinvent.com.

In order to participate in the AGM, shareholders with nominee-registered shares must request that their shares be temporarily owner-registered in the Euroclear shareholders' register. Such registration must be completed no later than Friday 18 March 2011 and the nominee must be informed of this well in advance of this date.

Shareholders must include their name, personal/company registration number, shareholding, telephone number and the name of any assistants that will be attending.

Proxy to act on behalf of a shareholder shall be sent together with the notice of attendance. Representative of a legal person shall hand in a copy of a registration certificate or similar papers of authorisation. The company will supply proxy forms upon request from a shareholder.

Upcoming financial reports

BioInvent will present the following financial reports:
Interim reports: 14 April, 14 July, 13 October 2011
Financial statement 2011: 9 February 2012

Investor Relations

Svein Mathisen, President and CEO,
+46 (0)46-286 85 50, mobile: +46 (0)708-97 82 13
BioInvent's financial reports are also aviable at www.bioinvent.com

Legal disclaimer

This annual report contains statements about the future consisting of subjective assumptions and forecats for future scenarios. Predictions for the future only apply as of the date they are made and by their very nature, in the same way as research and development work in the biotech segment, are associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this annual report.

BioInvent's Annual Report is produced in cooperation with ID kommunikation.
Photo: Lars Strandberg and stock photos from Getty Images.

BioInvent International AB (publ.)
Corp. ID 556537-7263
Address: Sölvegatan 41
Mailing address: SE-223 70 Lund
Tel: +46 (0)46-286 85 50
info@bioinvent.com
www.bioinvent.com

BIOINVENT